08.12.2015 Views

Brain pains

1R7vP5Z

1R7vP5Z

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

EditorialComment<br />

<strong>Brain</strong> <strong>pains</strong><br />

Editor: Mark Dugdale<br />

editor@ipprotheinternet.com<br />

Tel: +44 (0)203 750 6022<br />

Reporter: Tammy Facey<br />

tammyfacey@blackknightmedialtd.com<br />

Tel: +44 (0)203 750 6017<br />

Associate publisher: Carlos Northon<br />

carlosnorthon@ipprotheinternet.com<br />

Tel: +44 (0)203 750 6023<br />

Account manager: Malkeet Mullay<br />

malkeetmullay@ipprolifesciences.com<br />

Tel: +44 (0)203 750 6026<br />

Account manager: Kurtis Spencer<br />

Tel: +44 (0)203 750 6025<br />

Publisher: Justin Lawson<br />

justinlawson@ipprotheinternet.com<br />

Tel: +44 (0)203 750 6028<br />

Marketing executive: Amber Harty<br />

amberharty@blackknightmedialtd.com<br />

Tel: +44 (0)203 750 6020<br />

Designer: John Savage<br />

johnsavage@ipprotheinternet.com<br />

Tel: +44 (0)203 750 6021<br />

Office fax: +44 (0)20 8711 5985<br />

Published by Black Knight Media Ltd<br />

Provident House, 6-20 Burrell Row<br />

Beckenham, BR3 1AT, UK<br />

Company reg: 0719464<br />

Science and innovation are making incredible leaps forward, so much so that scientists from<br />

Ohio State University claim to have grown a nearly complete human brain—in a dish. The<br />

brain, which equals the maturity of a five-week old fetus, is the size of a pencil eraser. It has<br />

an identifiable structure and contains 99 percent of the genes present in the human fetal<br />

brain, according to its ‘growers’.<br />

The brain has a spinal cord, all of the major regions, multiple cell types, signaling circuitry,<br />

and even a retina. Rene Anand, professor of biological chemistry and pharmacology at Ohio<br />

State University, converted adult skin cells into pluripotent cells, which are immature stem<br />

cells that can be programmed to become any tissue in the body, to grow the brain.<br />

He said: “We’ve struggled for a long time trying to solve complex brain disease problems<br />

that cause tremendous pain and suffering. The power of this brain model bodes very well<br />

for human health because it gives us better and more relevant options to test and develop<br />

therapeutics other than rodents.”<br />

Scientists hope that the system will enable ethical, rapid and accurate testing of experimental<br />

drugs before the clinical trial stage, and advance studies of genetic and environmental<br />

causes of central nervous system disorders.<br />

Anand is yet to have his method peer reviewed because he has filed an invention disclosure<br />

with Ohio State University, so until it is scrutinised by other scientists, it’s unclear whether<br />

this is an actual breakthrough. But the possibilities are intriguing—in a decade that has<br />

brought us further expansion of the internet, the exploration of Pluto, driverless cars and<br />

solar-powered planes, we would be forgiven for thinking we’ve had our lot. But a scientist<br />

just grew a human brain—in a dish. Innovation is showing no signs of slowing down, and<br />

just like Anand’s method for growing a human brain, it needs protecting more than ever.<br />

With that in mind, we present this year’s IPPro The Annual. It covers intellectual property<br />

topics such as online brand protection, new gTLDs, and pharmaceutical research and<br />

development in detail, and provides a bird’s eye view of key jurisdictions around the world.<br />

As ever, we always welcome your feedback, so don’t hesitate to drop us a line.<br />

Mark Dugdale<br />

Editor<br />

Copyright © 2015 Black Knight Media Ltd.<br />

All rights reserved.<br />

3


Latin America is waiting<br />

AIPPI president Felipe Claro discusses<br />

issues the association has faced in the<br />

last 12 months, and what it plans to do<br />

during its annual congress in October<br />

2015 and beyond<br />

P8<br />

Give and take: enforcement’s<br />

unintended consequences<br />

Platform and brand owners can take an<br />

unexpected hit from social media site<br />

takedown disputes, say Susan O’Neill<br />

and Janie Thompson on behalf of INTA<br />

P16<br />

Backing the profession<br />

CIPA’s Lee Davies recaps what was a very productive 12 months for the institute<br />

P10<br />

Dealing with digital identity theft<br />

Nathalie Dreyfus of Dreyfus explains the<br />

importance of owning a trademark to<br />

protect a brand’s rights on the internet,<br />

and the various methods for doing so<br />

P20<br />

Top tips for TLDs<br />

Bart Mortelmans of bNamed.net offers<br />

advice for protecting trademarks online<br />

P28<br />

Growing into its own<br />

The new gTLD programme continues to develop and mature, according to Anthony<br />

Beltran of 101domain<br />

P24


Protect<br />

your IP<br />

worldwide.<br />

The most comprehensive and<br />

innovative IP translation, foreign filing<br />

and search services solution.<br />

• Ensure top quality.<br />

• Cut costs and save resources.<br />

• Simplify and streamline.<br />

Patent<br />

translations<br />

PCT national<br />

stage entry<br />

Direct<br />

filing<br />

European<br />

validation<br />

Patent<br />

searches<br />

International<br />

patent database<br />

Visit us at: inovia.com | rws.com


C<br />

M<br />

Y<br />

Deciding when to decide<br />

The lessons learned from the AIA<br />

aftershock prove that ongoing cooperation<br />

and partnership is the best way to achieve<br />

an organisation’s goals, says Matthew<br />

Sekac of Park IP Translations<br />

P34<br />

CM<br />

MY<br />

CY<br />

CMY<br />

K<br />

Perfecting patents<br />

Experts discuss how best to translate a<br />

patent, and what to look for in a partner<br />

P38<br />

One fell loophole:<br />

protecting clinical data<br />

There are evident loopholes in Mexican<br />

legislation regarding IP rights and clinical<br />

data protection framed in the scope<br />

of sanitary regulatory affairs. Soledad<br />

Betanzos-Lara of Goodrich, Riquelme y<br />

Asociados reports<br />

P56<br />

As queasy as 1, 2, 3<br />

Obtaining supplementary protection certificates<br />

in Poland is not as simple as do re mi, says<br />

Magdalena Tagowska of Patpol<br />

P52<br />

Innovation game:<br />

a new series<br />

Where are the next innovations<br />

going to come from? Experts take<br />

a look<br />

P46<br />

When only a wrecking ball will do<br />

The digital space can be a free-for-all for phony operators, so how do you catch the<br />

fake-happy counterfeiters? Experts from WebTMS and bNamed.net share how to limit<br />

the damage caused by online infringers<br />

P30<br />

The Kit Kat case:<br />

a break between the law and commercial reality?<br />

Experts from Christodoulos G. Vassiliades & Co. LLC examine the ways in which Europe<br />

and the UK have recently approached shape trademarks<br />

P58<br />

OAPI: effective<br />

trademark protection<br />

Vanessa Halle of Nico Halle & Co Law<br />

Firm offers some useful tips for brands<br />

protecting and enforcing their trademark<br />

rights in Africa<br />

P62<br />

Closing borders to fakers<br />

and pirates<br />

Amaka Okafor of Stillwaters Law outlines<br />

the importance of an effective border<br />

control regime to fighting counterfeiting<br />

and piracy<br />

P64<br />

Game-changing decisions on<br />

trademarks continue<br />

The Turkish Constitution and trademark<br />

law are at odds, but the courts are<br />

making attempts to clear up the disputes,<br />

says Oktay Simsek of Destek Patent<br />

P68<br />

Service providers<br />

A selection of providers in intellectual property<br />

P73


AIPPI president Felipe Claro discusses issues the association has<br />

faced in the last 12 months, and what it plans to do during its annual<br />

congress in October 2015 and beyond. Tammy Facey reports<br />

What has taken place over the past 12 months for<br />

the AIPPI? What have your members been focusing<br />

on in terms of intellectual property?<br />

We have been following the trademark changes in Europe through<br />

the trademark package initiative and have been participating in<br />

patent harmonisation studies in different jurisdictions.<br />

We are closely following the plain packaging debate before the<br />

World Trade Organization (WTO), where AIPPI (the International<br />

Association for the Protection of Intellectual Property) will deliver a<br />

presentation on IP as a trade resource during the public forum in<br />

Geneva at the end of September 2015. As WTO director Fernando<br />

Azevêdo said: “Trade should provide a seat for everyone at the table”.<br />

AIPPI also recently participated in a multi-jurisdictional copyright<br />

book project that will be available soon.<br />

Our observer status before Office for Harmonization in the Internal<br />

Market (OHIM) has been both demanding and rewarding, and we<br />

plan to return to Alicante in the future.


Given that your next congress is in Brazil, what can we<br />

expect on the agenda for your Latin American members?<br />

AIPPI is a global association that covers more than 120 jurisdictions.<br />

Our national groups, committees and individual members produce<br />

about 100 proposals for consideration in a given year. From those<br />

we identify four key topics that span the breadth of IP issues that<br />

are highly relevant for the IP community. These topics are chosen<br />

for detailed analysis and debate, leading to AIPPI resolutions. We<br />

also select a diverse range of topical panel sessions for our annual<br />

educational programme.<br />

This year, at our congress in Rio between 10 and 14 October 2015,<br />

we will debate trade secrets, free riding (trademarks), copyright<br />

exceptions and inventorship of multinational inventions. We are<br />

also taking into account several topics of interest proposed by the<br />

Brazilian group, so our panels will include sessions on plant variety<br />

protection and green technology. No one wants to be on the outside<br />

of green technology and climate change issues. Even the Pope is<br />

interested in climate change.<br />

How do you filter the proposals, to only end up with<br />

four IP issues?<br />

The first point is that in any given year there will always be more than<br />

four IP issues that AIPPI feels need to be addressed. As mentioned,<br />

the four issues selected annually form the basis of AIPPI’s resolutions.<br />

The power of these resolutions is that they represent the consensus<br />

view of AIPPI, having been studied by the national and regional<br />

groups, debated by experts and passed by vote at the executive<br />

committee. So the selection process is important.<br />

Topics of relevance to the IP issues facing the world today are proposed.<br />

Our programme committee meets to analyse all proposals and shortlists<br />

them for consideration by the reporter general team and ultimately<br />

approval by the bureau. This rigorous process ensures that relevant<br />

and diverse topics are selected for AIPPI’s resolutions. Similar rigour is<br />

applied to the selection of topics for the educational programme run at<br />

every congress, ensuring a balance of matters of global interest as well<br />

as topics of special interest for the region where the congress is held. We<br />

hope that this year we will attract more Latin American attendees keen to<br />

address IP issues they have in the region.<br />

We see that there is not much innovation protection in this part of<br />

America: only 2.5 percent of all patent applications come from Latin<br />

America. This number should rise in the future. We need to create<br />

more awareness of how to protect new technologies. Latin American<br />

people are innovating, but are not always ready or knowledgeable<br />

on how to protect their innovations. This needs to change.<br />

At the same time, there is a kind of anti-IP sentiment, especially<br />

among young people, who ask: “why should I pay for this?” This is<br />

particularly true in the virtual environment, because sometimes IP is<br />

reduced to just vibrations that travel through the air (books, games,<br />

apps, music, pictures, and movies). Even money is transformed into<br />

a fingerprint scan. So they ask: “Why it is so easy to get a file, but<br />

at the same time I am restricted from using it?”<br />

Would education practices raise awareness of IP<br />

and help Latin America become more innovative?<br />

Absolutely. IP awareness programmes are most welcome in the Latin<br />

America region. This should be done at all levels: schools, children,<br />

commerce, judiciary, and so on. Today, we no longer have local<br />

markets in the old sense. Even the smallest markets are affected<br />

by global IP rules and principles. In many cases the customer is the<br />

smartphone that dictates to its holder how and what to buy.<br />

How well positioned are IP systems in Latin America<br />

to encourage innovation in the life sciences?<br />

Culturally, innovation protection is a bit slow in Latin America. Only<br />

during the last few years are innovators realising they can protect<br />

their inventions with a patent or other means of protection. Typically,<br />

the order was to create and publish and do nothing. Innovators are<br />

now realising they can create, protect and then publish.<br />

Efforts are being made in this vein with universities taking the lead<br />

in developing innovation centres, shaping IP policies and spreading<br />

the message to create and protect. It is happening now and it will<br />

create an impact in the near future.<br />

I am optimistic about this. Latin American governments are<br />

also offering tax incentives for start-ups, so it would have<br />

a positive effect, even if it means there is more to comply<br />

with. IPPro<br />

“<br />

There is a kind of anti-IP sentiment, especially among young<br />

people, who ask: ‘why should I pay for this?’ This is particularly true<br />

in the virtual environment<br />

”<br />

Felipe Claro, President, AIPPI


CIPA<br />

Backing the profession<br />

CIPA’s Lee Davies recaps what was a very productive 12 months for the institute<br />

The 12 months over 2014 and 2015 were the first in the Chartered<br />

Institute of Patent Attorneys’s (CIPA) history that the positions of<br />

president and vice president have both been held by women. While a<br />

mark of progress today, we hope that in the near future, the same will<br />

be completely unremarkable.<br />

Also remarkable this year has been CIPA’s lobbying efforts. We have<br />

lobbied at home and abroad on critical issues such as the drafting<br />

and implementation of the Intellectual Property Bill, the unitary patent<br />

and the Unified Patent Court (UPC) and the consequences for UK<br />

PLC of a patent litigation system that was potentially damaging to the<br />

UK profession and the UK’s business interests.<br />

We also built on our relationships with other key stakeholders such<br />

as the IP minister, Baroness Neville-Rolfe, the UK IP Office (IPO) and<br />

the EU Commission. The IP minister delivered the keynote speech<br />

at the CIPA Congress, spoke alongside our president at a policy<br />

roundtable on cyber crime and was guest speaker at the inaugural<br />

meeting of a CIPA initiative to make the IP professions more inclusive<br />

and accessible to all, regardless of background.<br />

Ahead of the UK General Election, we produced our first ever<br />

manifesto, An Economy of Ideas. Through our manifesto, we implored<br />

10<br />

all political parties to see the IP system as not only a mechanism<br />

for protecting innovation, but also a significant means through which<br />

businesses maximise the return on investment.<br />

Months later, we continue to lobby the government to maintain the<br />

virtuous circle through which investment in new ideas is protected,<br />

leading to profits that can be reinvested in new and exciting projects.<br />

To accompany the manifesto and further illustrate the virtuous IP<br />

circle, we produced an animated video, also called An Economy of<br />

Ideas, which we launched on World IP Day (the video can be viewed<br />

on our website on YouTube).<br />

Significant attention has also been paid to the internal workings of<br />

CIPA. Andrea Brewster, 2013 and 2014 vice president and newly<br />

elected president for 2014 and 2015, embarked on a meet-themembers<br />

campaign. Brewster visits CIPA members in their own<br />

offices around the UK, to find out how best CIPA can serve them.<br />

In the same vein, our officers were set the challenge of describing<br />

the unique benefits of being a member of CIPA in three to five<br />

words. And when dealing with patent attorneys, three to five words<br />

can only translate into four words! “Status, Influence, Learning and<br />

Community” (SILC) formed the core of our three-year strategic plan.


Intellectual Property<br />

in an Innovative World


CIPA<br />

These four SILC headings have helped CIPA to align and prioritise its<br />

activities with a clear focus on what the institute should be doing for<br />

the people it represents. We have already made significant strides in<br />

delivering its objectives.<br />

Internal changes throughout the past year have reflected the foremost<br />

importance of serving members as well as possible. The Informals<br />

(the trainee arm of CIPA) felt isolated and unsupported. We have<br />

brought it closer. Now a formal CIPA committee, it has access to all<br />

of the institute’s support mechanisms, but the trainee attorneys also<br />

retain independence to decide their own programmes and set their<br />

own budget.<br />

Similarly, IP administrators, so vital to CIPA’s work, also sat on the<br />

fringes of the institute, either as associates with few clear membership<br />

benefits, or not joining at all. A new committee has been set up to look<br />

after their interests, its aims being to provide them with a voice at<br />

CIPA, professional recognition and influence, and a clearer career<br />

development pathway. A review and update of the existing—widely<br />

respected—patent administrators’ course, and the introduction of<br />

advanced training modules, is being overseen by the new committee.<br />

compliance with Privy Council requirements for the format of byelaws<br />

for chartered bodies.<br />

The last 12 months have also been a busy year for CIPA’s many<br />

committees. An internal governance committee has been established<br />

to ensure that the institute has in place robust governance<br />

procedures and leads on all finance, employment and general legal<br />

matters. A new education and professional standards committee<br />

has also been set up, and is providing CIPA with additional focus on<br />

educational matters.<br />

It is tasked with developing a long overdue set of professional<br />

standards detailing the skills and knowledge required for a twentyfirst<br />

century patent attorney, out of which CIPA is building a vibrant<br />

education programme.<br />

The joint business practice committee spent much of its time<br />

focusing on the impact of IPReg’s new client account requirements<br />

on patent and trademark firms. It also spent considerable energy<br />

lobbying against IPReg’s determination that the Money Laundering<br />

Regulations 2007 apply to patent attorneys.<br />

“<br />

CIPA sought to be as constructive as possible,<br />

however, the committee fears that the Nagoya Protocol<br />

has the capacity to cause severe difficulties for both<br />

academic and industrial researchers<br />

”<br />

Lee Davies, Chief executive, CIPA<br />

Following the successful introduction of a course covering formalities<br />

skills, CIPA has set up the IP administrators group (IPAG), membership<br />

of which is open to all members of CIPA who have an interest in IP<br />

administration. IPAG runs CPD qualification lectures and holds social<br />

events. It also publishes a newsletter, The PAN, which is produced<br />

each month.<br />

Embracing better technology is also all part and parcel of the ‘improved<br />

service’ CIPA model. We have introduced live web broadcasts from<br />

the CIPA Hall and venues around the country to bring high quality<br />

debate and information to a wider audience of our members and the<br />

outside world.<br />

It wasn’t just CIPA’s technology that required modernisation. CIPA’s<br />

bye-laws were unfit for purpose and needed substantial updating.<br />

As a professional body incorporated by Royal Charter, the bye-laws<br />

describe how CIPA is governed, structured and organised to deliver<br />

the objects set out in the charter.<br />

A resurgent trademark committee provided detailed comments<br />

to Office for Harmonization in the Internal Market in response to<br />

its strategic plan consultation. The committee conducted a survey<br />

of the CIPA membership to gain a better understanding of what<br />

support members who work in the trademark environment want<br />

from the institute. Some 457 members responded to the survey, a<br />

20 percent response rate. The committee discussed the results and<br />

was encouraged that support from CIPA on trademark issues is still<br />

wanted by the membership.<br />

The life sciences committee turned its attention to the European<br />

regulation to enforce the Nagoya Protocol, providing a consultation<br />

response which was well received by the Department of Food and<br />

Rural Affairs. The institute sought to be as constructive as possible,<br />

however, the committee fears that the Nagoya Protocol has the<br />

capacity to cause severe difficulties for both academic and industrial<br />

researchers. CIPA also published a position paper on the subject,<br />

which was well received by government and other major stakeholders.<br />

A working group was set up to consider possible amendments in<br />

greater detail and to prepare a draft set of bye-laws for discussion.<br />

After consulting members, the revised bye-laws will then be<br />

finalised after having been checked by specialist counsel for<br />

12<br />

This year, the patents committee has had one big item to consider—<br />

the unitary patent and UPC. Here there is great crossover with one<br />

of CIPA’s busiest committees, the litigation committee. When the UK<br />

IPO issued a technical review and called for evidence concerning


CIPA<br />

secondary legislation to implement the Unitary Patent Regulation<br />

and UPC Agreement, a joint working group of the two committees<br />

prepared CIPA’s response.<br />

The design and copyright committee led the institute’s work on<br />

examining the consequences of criminal sanctions for design<br />

infringement appearing in the IP Bill. The committee was central in<br />

determining CIPA’s lobbying position as we met with Lord Younger,<br />

Lord Clement-Jones and Lord Stevenson to set out our concerns.<br />

The international liaison committee has also had a very busy year.<br />

Members attended a reception hosted by Institute of Trade Mark<br />

Attorneys at the British Consulate-General in Hong Kong during<br />

International Trademark Association Annual Meeting, to which<br />

members of the All-China Patent Attorney Association (ACPAA)<br />

were also invited. A delegation visited Montreal in June 2014 at the<br />

invitation of the Intellectual Property Institute of Canada (IPIC,) to<br />

take part in discussions with IPIC council and to give a CPD seminar<br />

to IPIC members.<br />

In September 2014, a delegation from the ACPAA was welcomed by<br />

CIPA in Oxford, where they were treated to dinner at the Malmaison<br />

Hotel (formerly a prison!), followed the next day by a meeting with<br />

committee members and a CPD seminar, both held in beautiful<br />

autumnal surroundings at Worcester College.<br />

Members also welcomed several different groups from China to<br />

London, including: a group of judges from Yunnan Province, a group<br />

from Anhui Provincial IP Office, representatives of the Work Safety<br />

Department of the China National Space Administration in September,<br />

representatives of the China IP Society in October, and a group from<br />

the Department of Science and Technology and other technologybased<br />

institutions in Guangxi Zhuang Autonomous Region.<br />

Members of the committee met members of the Japan Patent<br />

Attorneys Association during the Asian Patent Attorneys Association<br />

(APAA) Congress in Toronto. CIPA members attending the APAA’s<br />

meeting hosted a reception in Malaysia for members of the Institute<br />

of Patent and Trade Mark Attorneys of Australia and were invited to<br />

a lunch with members of the Taiwan Patent Attorneys Association.<br />

CIPA’s charitable work also continued throughout 2014 and 2015. We<br />

co-founded Professions Week with several other leading professional<br />

bodies, helping young people to get the very best careers information,<br />

advice and guidance. Battle of the Bands made a welcome return to<br />

the CIPA social calendar. Hosted by Radio 1 DJ Scott Mills, the event<br />

saw patent attorneys perform their very best numbers in the aid of<br />

Generating Genius, which helps young people from disadvantaged<br />

backgrounds realise their potential by pursuing science, technology,<br />

engineering and mathematics subjects.<br />

CIPA is determined to continue to transform itself into a modern<br />

organisation that, as well as providing first-class services to its<br />

members, amplifies its external voice and educates business and the<br />

wider world on the importance of protecting IP.<br />

With a new website due to go live later in 2015, a major public<br />

event planned in partnership with the Science Museum and other<br />

developments in the pipeline, the coming year will only see CIPA<br />

growing in status and influence. IPPro<br />

14


Stillwaters Law Firm<br />

ADDRESS & CONTACT DETAILS<br />

2nd Floor 11, Awolowo Road, Ikoyi<br />

P. O. Box 56161, Ikoyi 101008, Lagos, Nigeria<br />

Tel: +234 (0) 1 454 7179, +234 (0) 1 460 5471<br />

Mobile: +234 (0) 803 324 8860<br />

Fax: +234 (0) 1 460 5470<br />

Email: info@stillwaterslaw.com<br />

www.stillwaterslaw.com<br />

STILLWATERS is an award winning law firm in Nigeria that specializes in intellectual property law,<br />

corporate and commercial, taxation and litigation. The firm operates from the commercial cities of<br />

Lagos and Abuja in Nigeria, with associate offices in Accra in Ghana and Douala in Cameroon.<br />

Professionalism, flexibility and innovation are the hallmark of our practice. We value professional<br />

excellence, outstanding result and realize they both require creativity and hard work. We strive to gain<br />

every legal advantage for our clients while upholding the principles behind the practice of law. Over<br />

the years, we have acquired considerable experience and an enviable reputation for rendering quality<br />

legal services in our areas of specialization.<br />

Practice representative clients include over 660 foreign multinationals, publicly-quoted companies,<br />

private companies, financial institutions, government institutions, industrial medium size businesses<br />

and individuals. Our practice is adequately equipped and well positioned to meet the challenges of<br />

legal practice in an ever-changing technological age.<br />

People . Integrity . Service<br />

• Trademarks Patents Designs<br />

• Copyright Anti-counterfeiting<br />

• Border Enforcement Measures Domains<br />

• Data Protection IP Litigation<br />

• IP Due Diligence Annuities<br />

• Transfer of Technology Piracy<br />

• Licensing Distributorship Franchising<br />

• Customs Related Assistance<br />

• Registrations Renewals Assignments


INTA<br />

Give and take:<br />

enforcement’s unintended consequences<br />

Platform and brand owners can take an unexpected hit from social<br />

media site takedown disputes, say Susan O’Neill and Janie Thompson<br />

By now, social media takedown policies are no secret to most brand<br />

owners as they are an often-used tool for a trademark or copyright<br />

holder to request the removal of infringing content such as trademark<br />

misuses, posts, videos, images, handles, or other pages from social<br />

media platforms. Recent litigation, however, suggests that platform<br />

and brand owners should exercise caution in initiating takedown<br />

procedures as plaintiffs are now naming both in lawsuits, alleging<br />

unwarranted takedowns.<br />

Social media platforms have been accused of failing to follow their<br />

own policies and procedures and taking down content without cause.<br />

16<br />

In Barshack v Twitter (6 May 2013), for example, the Barshacks filed<br />

suit in the US District Court for the District of Idaho against Twitter after<br />

the Barshack handle “@SunValley” was revoked and given to the other<br />

defendant, Sun Valley Company.<br />

The Barshacks alleged that Twitter did not follow its own takedown<br />

policy because it did not give them an opportunity to defend<br />

themselves or clear up any misunderstandings before revoking the<br />

handle. Consequently, the Barshacks sued Twitter for breach of<br />

contract and breach of the covenant of good faith and fair dealing,<br />

and sought an order to return their Twitter handle, an injunction


INTA<br />

“<br />

The Barshacks alleged that Twitter did not<br />

follow its own takedown policy because it did not give<br />

them an opportunity to defend themselves or clear up<br />

any misunderstandings before revoking the handle<br />

”<br />

Susan O’Neill, Internet committee member and partner, INTA and Hanson Bridgett LLP<br />

prohibiting Sun Valley Company from using it, as well as attorneys’<br />

fees, costs, and other expenses.<br />

Fortunately for platform owners, the court granted Twitter’s motion to<br />

dismiss on 19 September 2013, holding the breach of contract claim<br />

could not be sustained under the express language of Twitter’s service<br />

terms and “the implied covenant [of good faith and fair dealing] cannot<br />

be used to imply a contractual obligation that conflicts with the express<br />

terms of the contract”.<br />

Similar allegations against a social media platform were raised in<br />

Complexions v Complexions Day Spa and Wellness Center and<br />

Facebook (18 February 2011).<br />

In that case, plaintiff Complexions filed suit against Facebook in the<br />

District Court for the Northern District of New York because Facebook<br />

took down Complexions’s business page after Complexions Day Spa<br />

and Wellness Center sent a takedown notice.<br />

Among other claims, Complexions sought injunctive relief to restore its<br />

Facebook page, and alleged that the Facebook page was a valuable<br />

asset to its business and its loss resulted in sales and marketing<br />

potential losses that could not be fully remedied by money damages.<br />

The court, however, never reached the merits of the case, because<br />

Complexions voluntarily dismissed the action with prejudice.<br />

In both Barshack and Complexions, the brand owners that filed the<br />

takedown complaints at issue were also named as defendants and<br />

several other lawsuits have similarly been filed against brand owners<br />

that requested takedowns.<br />

In Elizabeth Ordonez v Icon Sky Holdings (30 August 2011), for<br />

example, the District Court for the Southern District of Florida granted<br />

damages and injunctive relief to dancer and choreographer Ordonez<br />

after Icon pursued unwarranted takedown requests.<br />

Ordonez, who used the stage name Elizabeth Sky, claimed that Icon<br />

committed acts of tortious interference with contractual relationships<br />

between herself and social media sites by making misleading<br />

complaints of trademark infringement over her use of the stage name<br />

Elizabeth Sky and related social media profiles.<br />

Additionally, Ordonez claimed that Icon engaged in deceptive and<br />

unfair trade practices by sending messages misrepresenting that she<br />

was committing fraud and by taking over her social media profiles and<br />

Twitter handle. After Icon failed to appear in the case, the court entered<br />

judgement in favour of Ordonez.<br />

The court held that she had contractual relationships with the social<br />

media sites based on the “terms of use” and Icon interfered with<br />

those relationships by making complaints that resulted in Ordonez’s<br />

accounts getting cancelled. Ultimately, the court granted injunctive<br />

relief, $81,000 in damages, and attorneys’ fees and costs.<br />

Failing to investigate before requesting a takedown may pose an<br />

additional risk for brand owners. In Kim v Coach, the plaintiffs, who<br />

were selling Coach merchandise on eBay, filed a class action in the<br />

District Court for the Western District of Washington against Coach<br />

for failing to perform a reasonable investigation to determine if<br />

products advertised on eBay were in fact counterfeit before initiating<br />

the takedown process. According to the plaintiffs, Coach’s complaints<br />

“<br />

Brand owners should consider how<br />

best to deliver their message to the alleged infringer,<br />

particularly if the individual is a fan or<br />

supporter of the brand<br />

”<br />

17<br />

Janie Thompson, Associate, Hanson Bridgett LLP


INTA<br />

led to their ads being removed from eBay and their accounts being<br />

disabled. The plaintiffs further alleged that Coach sent letters to them<br />

claiming that they were infringing Coach’s trademarks and demanding<br />

payment to settle the issue.<br />

Based on these alleged facts, the plaintiffs filed claims for violations<br />

of the Washington Consumer Protection Act, misrepresentation of<br />

trademark infringement, defamation, and tortious interference with a<br />

business expectancy.<br />

Coach filed a counterclaim against the plaintiff’s attorneys for<br />

defamation, and the parties ultimately stipulated to dismissal of the<br />

case with prejudice.<br />

Brand owners may also be accused of bullying after initiating a takedown<br />

request or other litigation, as was the case in CrossFit v Alvies (22<br />

January 2014). Plaintiff CrossFit filed a trademark infringement suit<br />

in the District Court for the Northern District of California alleging that<br />

defendant Jenni Alvies infringed its trademark through her use of a<br />

blog at crossfitmamas.blogspot.com and her use of a ‘CrossFit Mamas’<br />

Facebook page. Alvies accused CrossFit of being a cyberbully and<br />

counterclaimed for declaratory judgment of non-infringement, as well<br />

as unfair competition and false advertising.<br />

One of the allegations stated that CrossFit improperly invoked the Digital<br />

Millennium Copyright Act in its takedown notice to Facebook because<br />

Crossfit’s claims were based on trademark rights and not copyright.<br />

When CrossFit filed a motion to dismiss and argued that they similarly<br />

would have succeeded in a trademark takedown request, the court<br />

declined to “hypothesise about what Facebook would or would not<br />

have done if it had received a trademark takedown notice regarding<br />

Alvies’s Facebook page”.<br />

The court further declined to determine in a motion to dismiss that<br />

Alvies’s Facebook page constituted infringement. Alvies’s other<br />

claims were dismissed with leave to amend. Ultimately, the parties<br />

settled and stipulated to a final judgement.<br />

In light of this recent litigation, social media platforms may be more<br />

cautious in implementing their removal policies. Similarly, brand<br />

owners may be more cautious when evaluating an infringement<br />

accusation before requesting takedowns. In addition, brand owners<br />

may want to be more creative in approaching the issue, especially in<br />

less clear-cut cases.<br />

For example, brand owners should consider how best to deliver their<br />

message to the alleged infringer, particularly if the individual is a fan<br />

or supporter of the brand. In some cases, it may be helpful to see<br />

what can be done through direct communication with the individual or<br />

on a business-to-business level.<br />

Hopefully, with creativity and open dialogue, brand owners can<br />

resolve any issues in a way that works for all of the parties involved—<br />

without any unwanted litigation. IPPro<br />

18


Just as in the real world, distinctive signs have a major economic value<br />

on the internet. These signs are subject to numerous infringements on<br />

the web due to this economic value.<br />

Historically, on Web 1.0, infringements essentially related to domain<br />

names. Cybersquatting is one such example. This involves a third<br />

party, acting in bad faith, taking undue advantage of the “first-come,<br />

first-served’ principle, on which the registration of domain names is<br />

based, in order to register trademarks on which they have no right, with<br />

the intention of then reselling them to the actual trademark owners.<br />

Furthermore, on 26 June 2008, the Internet Corporation for<br />

Assigned Names and Numbers (ICANN) confirmed its decision<br />

to give to the public the possibility of creating new gTLDs. The<br />

opening up of new generic extensions involves high economic<br />

stakes. However, it also leads to an increase in cybersquatting<br />

risks. Fortunately, trademark ownership constitutes an effective<br />

tool to protect one’s rights on the internet.<br />

Trademarks and extrajudiciary resolution for<br />

disputes relating to domain names<br />

With the creation of the Google AdWords advertising programme in<br />

the 2000s, a new type of trademark infringement developed on the<br />

internet. This programme gave rise to significant disputes due to<br />

certain websites using the trademarks of third parties as keywords to<br />

direct internet users to their webpages. With the emergence of Web<br />

2.0, today, the infringement of trademark rights can also be seen on<br />

social networks.<br />

20<br />

Extrajudiciary dispute resolution mechanisms are alternative methods<br />

for settling disputes available to trademark owners. Such alternative<br />

methods offer a number of advantages as they are transnational,<br />

quick, relatively cheap and are entirely conducted online.<br />

The most commonly used alternative resolution procedure is the<br />

Uniform Dispute Resolution Policy (UDRP). This procedure is only


TrademarksOnline<br />

open to gTLDs, as well as to some country code TLDs. According to<br />

Paragraph 4 of the UDRP, the procedure is only available for disputes<br />

on the following conditions: (i) the domain name in dispute must be<br />

identical or confusingly similar to a trademark in which the complainant<br />

has rights; (ii) the third party must not have any right or legitimate<br />

interest in respect of the domain name; and (iii) the third party must be<br />

of bad faith.<br />

Being a rightful trademark owner is important as the UDRP procedure<br />

is only open to trademark owners. In this light, in a 2006 decision<br />

involving Geopack, the complainant invoked as the basis for the<br />

UDRP procedure its trade name Geopack and domain name geopackindustries.com,<br />

of which the respondent was aware.<br />

The complaint was dismissed because the complainant was unable to<br />

show that it was the rightful trademark owner.<br />

While the UDRP policy provides that the complainant must be the<br />

rightful trademark owner, it is however silent on what trademark<br />

ownership means. Must the trademark be registered? It has been held<br />

in several decisions that complainants do not have the obligation under<br />

the UDRP policy to base their complaints on a registered trademark.<br />

Complainants can therefore rely on trademarks that require no<br />

registration formalities, such as common law trademarks.<br />

To ensure equal treatment, according to case law, all complainants<br />

can rely on a common law trademark. The complainant must then<br />

show that the mark is connected to goods or services, ie, it fulfils its<br />

essential function of indicating the origin of the goods or services. In<br />

the 2000 Julia Roberts v Russell Boyd case, as well as that of Brad Pitt<br />

v Mircea Roibu in 2010, it was held that even though the trademark is<br />

not registered, a personality right can confer rights on a common law<br />

trademark due to sufficient connection with the complainants.<br />

To complement the UDRP procedure, ICANN set up the Uniform<br />

Rapid Suspension (URS) procedure in order to enhance the<br />

protection of rights with the advent of new gTLDs. This procedure<br />

adopts the same conditions as the UDRP procedure, but it is quicker<br />

and relatively cheaper.<br />

The URS procedure was set up to quickly assist rightful owners<br />

in cases of flagrant infringements. Indeed, URS complaints are<br />

much shorter than UDRP complaints (URS complaints are limited<br />

to 500 words while UDRP complaints are limited to 5,000 words).<br />

However, this procedure does not allow for the transfer or removal<br />

of the domain name but it only allows its suspension for the<br />

period of one year. Once again, the procedure is only available to<br />

trademark owners.<br />

The use of alternative dispute resolution methods does not in any<br />

way prevent trademark owners from going through the classical<br />

judicial route in order to protect their rights on the internet.<br />

Trademarks and Trademark Clearinghouse<br />

In light of the infringement risks brought on by the creation of new<br />

gTLDs, and in order to protect trademark owners, on 26 March 2013,<br />

ICANN set up the Trademark Clearinghouse (TMCH). The TMCH is a<br />

database of trademarks filed by their owners. Filing a trademark in the<br />

TMCH has two major benefits.<br />

Firstly, it allows the pre-registration of the trademark with the new<br />

gTLDs for a specific period, called sunrise. Indeed, when launching a<br />

new extension, the registry of the extension must provide a minimum<br />

period of 30 days during which a trademark owner that filed the<br />

trademark with the TCMH gets first priority to register a domain name<br />

bearing this extension.<br />

Secondly, once the sunrise period has elapsed, registering a trademark<br />

in the TMCH allows the trademark owner to be notified about third<br />

party attempts to register a domain name linked to the trademark.<br />

This notification service is called the Trademark Claims Service. The<br />

notification then allows the trademark owner to take action against<br />

the registration of the domain name through the URS and effectively<br />

protect its rights on the internet.<br />

It is necessary to show trademark ownership in order to have access<br />

to this system. The TMCH only accepts registered trademarks, courtvalidated<br />

trademarks and trademarks protected by applicable statutes<br />

and treaties. As such, unregistered trademarks, including common law<br />

trademarks, meet the eligibility requirements of the TMCH.<br />

Trademarks and Google AdWords advertising<br />

Trademark ownership can also come in very handy to protect one’s<br />

rights in case of infringements through fraudulent use of a distinctive<br />

sign as a keyword for referencing with Google ads. Since the Google<br />

AdWords case before the European Court of Justice on 23 March<br />

“<br />

It is necessary to show trademark ownership<br />

in order to have access to this system. The TMCH only<br />

accepts registered trademarks, court-validated trademarks<br />

and trademarks protectedby applicable statutes and treaties<br />

”<br />

Nathalie Dreyfus, Trademark attorney, Dreyfus<br />

21


TrademarksOnline<br />

2010, it is now established case law that Google cannot be held liable<br />

for trademark infringements as long as its role is only that of a passive<br />

technical service provider. However, trademark owners can sue the<br />

advertiser if it is impossible or difficult to distinguish the advertisements<br />

from the natural results, which creates a risk of confusion for the<br />

internet user.<br />

In this light, in a case dated 29 November 2011, the French Court of<br />

Cassation held the advertiser liable. The case centred on the issue of the<br />

reservation by a competitor of the trademarks ‘Heden’, ‘Max-In-Power’<br />

and ‘PCA France as keywords in order to redirect, via a sponsored<br />

link, towards websites reselling electronic products marketed under<br />

another trademark. It was impossible or difficult for the internet user to<br />

know whether the products covered by the advertisement came from<br />

the owner of the trademarks used as keywords or from an economically<br />

affiliated company. It was consequently held that there was indeed<br />

a risk of confusion and a fortiori, an infringement of the purpose of<br />

indicating the origin of the trademark.<br />

However, the main advantage of trademark owners in protecting their<br />

rights against an infringement resulting from Google AdWords does<br />

not lie with the courts but rather, in the online mechanism set up by<br />

Google. Indeed, trademark owners can notify any infringement of their<br />

rights to Google by filling out a trademark complaint form.<br />

If the advertiser has no legitimate right, Google will remove the<br />

fraudulently used trademark as a keyword from the Google Adwords<br />

referencing system. In this way, the trademark owner benefits from<br />

a quick, simple and free mechanism to protect itself against such<br />

infringements on trademark rights.<br />

Trademarks and social networks<br />

Lastly, being a trademark owner is essential in order to protect oneself<br />

in case of infringements on social networks. As these platforms<br />

now serve as vital tools for professionals, the usernames on social<br />

networks have acquired an economic value and so are often subject to<br />

infringement. While each social network has its own operating method<br />

and its own characteristics, they are all based on registration followed<br />

by the allocation of a user account. The username is allocated to the<br />

first person who requests it. With the reservation of a username being<br />

free, usurpation is easy.<br />

It is possible for a username to be unavailable for the legitimate<br />

trademark owner because it was unduly registered by a third party. This<br />

practice consisting of registering a username on which a third party<br />

has rights is generally termed as ‘username squatting’. Fortunately,<br />

social networks generally provide an online notification mechanism in<br />

case of trademark infringement.<br />

Article 1(a) of the Facebook Pages Terms states: “A page for a brand,<br />

entity, or public figure may be administered only by an authorised<br />

representative of that brand, entity or public figure.” In case of noncompliance<br />

with those terms and in particular in the case of username<br />

squatting, an online mechanism allows the trademark owner to report an<br />

infringement. In case of infringement, Facebook will cancel the username.<br />

To conclude, with the significant development of the internet, it is vital<br />

for brands to protect their digital identities. To this end, it is clear from<br />

the above that trademarks are an essential tool that can prove to be<br />

very effective against various types of infringements. IPPro<br />

22


Park IP Translations<br />

• Protect Global Brands<br />

• Minimize Risk<br />

• Easy-To-Use Client Portal, Resources + Technology for Real-Time Information<br />

• Streamlined Foreign Filing Process<br />

• Expert Translation + Foreign Filling Services<br />

• Increase in Quality Control<br />

The Leader in International Patent<br />

Prosecution and Litigation<br />

Language Services<br />

CONTACT US TODAY<br />

info@parkip.com<br />

parkip.com


Growing into its own<br />

The New gTLD programme continues to develop and mature,<br />

says Anthony Beltran of 101domain<br />

It has been well publicised that the domain name industry, and the<br />

Internet Corporation for Assigned Names and Numbers (ICANN)<br />

specifically, has missed the mark in the first year of its much lauded<br />

new gTLD programme. ICANN, the US-based organisation whose<br />

responsibility includes developing policy and ensuring the operational<br />

success of the global internet, estimated in early 2014 that its new<br />

gTLD programme would generate 33 million new domain registrations in<br />

extensions such as .guru, .club, .realtor, .nyc and more. ICANN revised<br />

its estimates downward a year later to 15 million names.<br />

Where did we land? Six million names or so—not impressive by<br />

any measurement.<br />

As an executive of a domain name registrar that has invested heavily<br />

in the new gTLD programme, I am of course going to be optimistic in<br />

my opinion of the success and long-term viability of the new gTLD<br />

programme. My job is to market the value of domain names and to<br />

promote and sell these names to customers around the world. But the<br />

fact is, the industry has a long way to go until new gTLDs become a<br />

fixture on the internet landscape. I’m going to break down some of the<br />

areas in which the industry has fallen short, and the changes I see<br />

happening today, which will help new gTLDs elevate to success.<br />

Public awareness<br />

It took six years of industry policymaking from 2008 to 2014 until the<br />

first new gTLDs under this programme were launched. The process<br />

was arduous and involved many stakeholders and many trying times<br />

of debate and negotiation. Once the green light was given, new<br />

gTLD applicants quickly shifted their attention to getting their registry


agreements signed and their extensions launched. It seemed that<br />

actually marketing these hundreds of new products was an afterthought<br />

at first. Back then, the attitude of many of the new gTLD applicants<br />

was that if they put their TLD out, there was so much pent-up demand<br />

that people would buy them by the hundreds of thousands.<br />

Looking back, this was certainly not the case. What we saw was the<br />

launch of the first groups of new gTLDs with lukewarm results. It became<br />

quickly apparent that the only purchasers of these newly available,<br />

‘highly demanded’ domain names were domain investors and to some<br />

extent brand and trademark holders, if only from a defensive registration<br />

position. This lukewarm response continued throughout 2014 with the<br />

release of hundreds of new domain extensions, albeit with a few bright<br />

spots, such as the great effort put forth by the .club registry, whose<br />

volume of active registrations has reached nearly 300,000.<br />

What happened? New gTLD registries pushed these new domain<br />

names through registrars, relying on them to advertise and market all<br />

of these new products through their normal channels. Once customers<br />

saw these new names, they would buy, right? The flaw in this reasoning<br />

was that registrars were primarily faced with the enormous burden of<br />

simply launching this onslaught of new domain names. Launch process<br />

were highly complex and filled with brand new legal, technical and policy<br />

processes. We didn’t see much active advertising or marketing through<br />

registrar channels as they were busy just keeping up.<br />

To put things in proper perspective, the domain industry has seen 21<br />

gTLDs launched since the internet was created 30 years ago. In 2014,<br />

it saw 300 new gTLDs launched. At the time of writing, the total has<br />

increased to more than 600.<br />

Today, we are seeing registries approach their product launches in a<br />

much different way. Strategy has shifted from relying on the registrar<br />

channel to advertise and market all of these new products, to registries<br />

actively promoting and driving customers through the registrar channel.<br />

Registries are becoming much more aggressive in reaching their target<br />

audiences in new and creative ways. Let’s take these as examples:<br />

.Bank: at nearly $1,000 per year for a domain name, the .bank registry<br />

has successfully worked with the American Bankers Association (ABA)<br />

to generate a few thousand registrations. The registry generated<br />

interest in, and positioned the value of, the .bank extension across the<br />

banking industry, directing sales to accredited registrars. .Bank is a<br />

unique TLD because it has very specific requirements geared towards


NewgTLDs<br />

banking institutions and security. I expect to see this TLD build a very<br />

nice and widely used space for itself over time.<br />

.Sucks: if you have anything to do with intellectual property, you know<br />

what this TLD is about. There has been a lot of controversy around<br />

.sucks and the registry has led some pretty high-profile marketing<br />

campaigns online and offline, making waves along the way. Whatever<br />

your thoughts on .sucks, you cannot deny that it did a good job in<br />

elevating the visibility of the TLD and the new gTLD programme in<br />

general. Brand owners should pay attention to this one.<br />

.Votel.voto: this TLD is an interesting one managed by the registry<br />

Afilias, operator of .info, .pro, and many more TLDs. The registry has<br />

managed to build key partnerships within political communities as<br />

well as sign up various US states to use their TLDs (for example,<br />

arizona.vote and alabama.vote) in high profile political awareness<br />

campaigns. With presidential elections starting to gain momentum in<br />

the US, political parties are starting to oil up their marketing machines.<br />

Using short, memorable domain names fit extremely well in these very<br />

public efforts.<br />

.Law: Mind + Machines, the registry behind the .law extension, recently<br />

announced a partnership with ALM Media, a leading international legal<br />

media company. As part of the partnership, ALM will roll out more<br />

than 100 domain names with the .law ending across its existing web<br />

properties and new product lines. It will also be marketing the .law TLD<br />

throughout its channels to raise awareness in the industry. The TLD is<br />

restricted to credentialed legal practitioners to provide a trusted space<br />

for the legal community to connect with its clients.<br />

Brand participation<br />

To this point, we have not seen a lot of participation from .brand new<br />

gTLD applicants. This has been by design for many of the 600 or so<br />

companies that applied for their own TLDs. Early on, ICANN granted an<br />

extension until 29 July 2015 for .brand applicants to sign their registry<br />

agreements, which has delayed .brand adoption and has allowed<br />

brands to defer costs and any decision making on their .brand new gTLD<br />

strategies. Many brands have been using a wait-and-see approach to<br />

determine what their next steps would be based on industry feedback<br />

and public adoption of new domain names in general.<br />

Now that the deadline is here, brands are being forced to make<br />

decisions. Once registry agreements are signed, operating costs start<br />

accruing for their TLDs. I expect to see much more activity in the .brand<br />

sector of the new gTLD programme through the rest of 2015. When we<br />

see larger consumer brands roll out their own domain extensions, new<br />

gTLDs will certainly start making their way into the mainstream.<br />

The best is yet to come<br />

We are approaching nearly 400 new gTLDs available to the general<br />

public, at the time of writing. More than half of these launches have<br />

secured fewer than 5,000 registrations. Just over 100 have secured<br />

more than 10,000 registrations. Some of the top TLDs in terms of<br />

registration volume, such as .xyz, .science, .party, and .top, have been<br />

sold for nothing, or next to nothing, and have generated very little<br />

usage. Many others, such as .link, .click, and .property, have been<br />

registered by the registries themselves so they don’t really count. This<br />

is not an indicator of the overall success of the new gTLD programme.<br />

As planned by ICANN, the domain extensions that have been widely<br />

anticipated, as well as many restricted TLDs that are sure to find their<br />

place in various industries across the globe, have yet to be released.<br />

TLDs such as .web, .shop, .music, .film and .app will be rolling out<br />

soon. You can bet that the companies that end up winning and<br />

operating these domain extensions have big plans to push them into<br />

the public mainstream.<br />

Launches to watch in the near future include regulated extensions<br />

such as .insurance and .film, which have the potential of gathering<br />

wide-ranging support in their respective industries. These regulated<br />

TLDs have the ability to reach consumers on a mass scale for specific<br />

purposes, which is what is needed to create a healthy and thriving<br />

domain space.<br />

In summary, we are still very much in the early stages of the ambitious<br />

new gTLD programme. The new gTLD programme continues to<br />

develop and gain momentum and has a long way to go to reach full<br />

maturity. Technology moves fast. Whether you are an IP practitioner<br />

or brand owner, it is still important that you stay informed about the<br />

developments in the space so that you may advise your clients or your<br />

stakeholders properly without being left behind. IPPro<br />

“<br />

Whatever your thoughts on .sucks,<br />

you cannot deny that it did a good job in elevating<br />

the visibility of the TLD and the new gTLD programme<br />

in general. Brand owners should pay attention to this one<br />

”<br />

Anthony Beltran, COO/CFO, 101domain<br />

26


CGV<br />

CHRISTODOULOS G.VASSILIADES & CO. LLC<br />

Advocates - Legal Consultants<br />

LEGAL EXPERTISE INTERNATIONAL REACH<br />

AFFILIATED OFFICES IN 7 COUNTRIES<br />

INTELLECTUAL PROPERTY<br />

Corporate & Commercial | Migration<br />

Shipping | Contractual Drafting<br />

Mergers & Acquisitions | Banking & Finance<br />

Tax & International Tax Planning<br />

The vessel of freedom<br />

Cyprus Russia Greece Belize Malta<br />

Hungary Seychelles China<br />

30years of excellence<br />

1984 -2014<br />

Contact us: Email: cgv@vasslaw.net / iplaw@vasslaw.net | Tel.: +357 22 55 66 77 | Tel.: +357 22 55 66 77<br />

www.vasslaw.com


Bart Mortelmans of bNamed.net offers advice for protecting trademarks online


DomainNames<br />

Managing a domain name registration programme is an unenviable task.<br />

Hundreds of extensions exist in various guises—country-codes, generics<br />

and the old bastions of the internet, including .com—and knowing which<br />

way to point your brand, or how to prioritise trademarks, can easily keep<br />

you up at night.<br />

Luckily, there are number of tips and tricks that you can learn that will<br />

make any registration programme easier to manage.<br />

First of all, plan extensively. There are many partners out there that will<br />

assist with registrations, but they do not know your products, markets<br />

or customers like you do, so put some thought into where you want<br />

to register your trademarks. It’s also worth remembering that, with the<br />

advent of new gTLDs, there are just too many extensions to make it<br />

possible to protect your trademarks across the board. In the past, many<br />

of our clients would register their trademarks in every TLD and countrycode<br />

TLD, but that is no longer a cost-effective solution but for a handful<br />

of trademark owners.<br />

spammer, who warns of a similar registration in an extension nobody<br />

has ever heard of via email. Do not be fooled by these—trademark<br />

owners don’t need registrations in these extensions, which are often<br />

very remote and sparingly used country code TLDs. Of course, as a<br />

trademark owner, you might be interested in launching in that particular<br />

market in the future, but in that case, close the spam email and seek out<br />

legitimate agents or registrars. The internet is full of phonies purporting<br />

to offer domain name registration services.<br />

If you notice that someone has actually registered your trademark<br />

under an extension that you do not care about, you should address<br />

this to them and let them know that they should not be doing it. A<br />

standard letter via registered mail will suffice. These instances are not<br />

worth an investment in dispute resolution. The minimum, a cease and<br />

desist letter, is all that is required, because registrations in extensions<br />

that no one uses should not keep you up at night. These domains are<br />

often dropped when they the time comes for them to be renewed, so<br />

you’ll be able to secure them anyway.<br />

The most important extensions will be the ones where your customers<br />

expect to find your brand. Many internet users, especially outside of the<br />

A more proactive course of action would be to block domain names.<br />

Donuts, the owner of almost 200 new gTLDs, offers the Domains<br />

“<br />

A common pest of trademark owners is the spammer, who<br />

warns of a similar registration in an extension nobody has ever<br />

heard of via email. Do not be fooled by these<br />

”<br />

Bart Mortelmans, Managing director and founder, bNamed.net<br />

US, expect a trademark to be available in the country code TLD that<br />

corresponds to his or her location. A Spanish internet user might expect<br />

to see the website hosted on a .es domain. You should prioritise your<br />

registrations that way—where you have customers, have a domain<br />

name, because representation wherever you are present is vital.<br />

Protected Marks List (DPML), which allows a single trademark to be<br />

blocked from registration across dozens of extensions, for a reasonably<br />

low fee. The DPML is particularly attractive if you want to employ a<br />

broad strategy, otherwise you should stick to the extensions that are<br />

important to your brand.<br />

Equally important is use. We encourage clients to make sure they<br />

use these domain names. Of course, a trademark owner can park a<br />

domain, but why not put them to better use? If your main website is<br />

under the .com banner, it makes sense to redirect your .fr domain to<br />

your .com address, because a lot of French internet users will expect<br />

to be able to access your website through their local, and most familiar,<br />

country code TLD.<br />

Any registration programme becomes more complicated when new<br />

gTLDs are added to the mix. Today, extensions are no longer limited<br />

to country or memorable generic. Domains are available in hundreds<br />

of extensions, many of them market-specific. The trick is to pick new<br />

gTLDs that correspond to the markets in which you are active, much<br />

in the same way as country code TLDs. For example, it makes sense<br />

to register a domain in .bike if that is your main business, whereas a<br />

building company would not benefit from a .bike registration.<br />

Domain name enforcement<br />

Managing a domain name enforcement programme is as daunting<br />

as proactive registrations. A common pest of trademark owners is the<br />

29<br />

Finally, make sure that you are the actual owner of the domain name.<br />

Often, particularly with small businesses, the wrong person registers<br />

the domain name and the actual owner is not listed in Whois. Make<br />

sure that does not happen. We have seen many cases where a domain<br />

name is held for ransom when there is a dispute over invoices and<br />

payments between the web designer and the business, for example.<br />

Even though not directly related to the domain name, it can be used<br />

as a bargaining chip.<br />

When all is said and done, the most important trick is really the most<br />

obvious—check the availability of the domain name. You must not<br />

wait for your counsel to check whether a trademark is available before<br />

launching a new product or in a new market, for example.<br />

Our website has a search function that allows anyone to search for<br />

domain names across TLDs—it’s that simple. Also, don’t be worried if the<br />

.com is not available. A lot of .com domain names are reserved for sale.<br />

That might not be ideal, having to pay extra money for that online real<br />

estate, but if you are going to go ahead with a product launch, then it<br />

might be worth the extra expense. IPPro


When only a wrecking ball will do<br />

The digital space can be a free-for-all for phony operators, so how do<br />

you catch the fake-happy counterfeiters? Experts from WebTMS and<br />

bNamed.net share how to limit the damage caused by online infringers


Bart Mortelmans<br />

Managing director and founder<br />

bNamed.net<br />

Nick March<br />

IP business development manager<br />

WebTMS<br />

Fakes are available online in increasingly large<br />

numbers—who is producing these goods, and how<br />

are they doing it on such a scale?<br />

Nick March: Fakes appearing in the marketplace is not a new<br />

problem. We’ve all seen market traders selling their fake shirts,<br />

jeans and designer handbags and more.This has happened for<br />

years on a smaller scale in the UK, and in much larger scales<br />

abroad, in countries such as Thailand, with a large concentration<br />

of fakes coming from Asia, in particular China.<br />

With the huge increase in the number of people across the globe<br />

getting connected to the internet, it’s no surprise that this has<br />

bought fake consumer goods to the masses.<br />

Organised crime syndicates are often behind the large-scale<br />

production and distribution of fake items. For them it is a means of<br />

creating large sums of money to be re-invested into illegal money<br />

making avenues, to grow their illicit empires. A large majority of<br />

fakes also originate from China, where labour is cheap and it is<br />

not uncommon for the authorities to look the other way.<br />

The internet plays a huge part in enabling these gangs to achieve<br />

such a wide reach, with auction sites, social media and private<br />

advert websites being top of the list. It’s not that these sites condone<br />

this behaviour, it’s simply such a large undertaking to effectively<br />

manage and track, although most well established websites have a<br />

protocol in place for reporting offending products, which hopefully<br />

leads to them being withdrawn from their respective marketplace.<br />

Counterfeiting is a global problem, particularly for<br />

international brands—how can legal counsel tackle<br />

fakes produced abroad?<br />

March: Depending on the budget available, there are a number<br />

of steps that can be taken to increase damage limitation that are<br />

beyond trademark, design and patent registration, which would be<br />

the foundation of your intellectual property protection. Some of the<br />

additional steps that can be taken are:<br />

• Customs recordals: lodge customs recordals with the local<br />

authorities. If you’re concerned that fakes are making their<br />

way into a particular jurisdiction, you could check to see if that<br />

particular country has a customs recordal system in place.<br />

This usually involves the formality of filling out forms that<br />

state which products you would like them to look out for (be<br />

it the design, brand name or both) and in some instances,<br />

the actual trademark protection you have in place related to<br />

these brands that you would like them to monitor. With the<br />

formality lodged with customs officials, you will increase the<br />

likelihood of fake products being questioned by officials, who<br />

will contact you to check the authenticity of the product.<br />

• Private investigations: there are many companies that<br />

specialise in the niche area of private investigations relating<br />

to IP and you should use one based locally to the problem.


TrademarkProtection<br />

Depending on your budget, they can provide different levels of<br />

data, including simply whether fakes exist, where are the fakes<br />

made and the name of the producer. At the higher end, they<br />

can also be quite cunning in their techniques and enquire about<br />

potential orders so you can gauge the size of the operation.<br />

Other information that can be acquired is how long the operation<br />

has been running and if there are any affiliated companies,<br />

which in all probability are also manufacturing fake products.<br />

• Watching service providers: most of the well-known<br />

companies in this arena have already expanded their services<br />

and branched out into this area, which in itself is rather telling<br />

that a large problem exists in the first place. The services<br />

offered tend to range from company to company but in essence<br />

they will be able to perform a health check of your brand<br />

online, ie, how many sites were found selling your product, list<br />

all the sites and products, and so on. They can also continue<br />

to monitor the presence of new fake products appearing in<br />

any online marketplaces. As well as these channels, they<br />

can also check for and monitor new domain names coming<br />

into existence that are clearly infringing on the actual brand<br />

owner’s rights. If domain names registered to counterfeit<br />

manufacturers or indeed anyone else who is not the rightful<br />

owner are found, the domain names are reported to the<br />

brand owner. The brand owner will then have an opportunity<br />

to object via various dispute resolution systems currently in<br />

place. These were setup in order to help the rightful owners of<br />

trademarks take ownership of their related domain names and<br />

to ensure there are no other companies with similar domain<br />

names trying to pass themselves off as legitimate.<br />

How does online enforcement differ to offline<br />

enforcement, and how should brands tweak their<br />

strategies to suit each?<br />

March: When discussing tangible products, the source or origin<br />

of all counterfeits/fakes begins offline, ie, the manufacturing of<br />

the product has to exist for there to be something to pass off as<br />

something else.<br />

So in essence, the root of the problem has to be extinguished at<br />

source using people on the ground to physically see the problem,<br />

report on the problem, and hopefully be part of a team to secure<br />

the closure of the illicit locations that are producing large amounts<br />

of fakes.<br />

The online element is really just another avenue for the counterfeit<br />

products to be exploited. As mentioned, this can be monitored<br />

and managed to some degree of effectiveness, however, without<br />

eradicating the source, it’s highly likely that new fake sites trying to<br />

pass themselves off as legitimate will continue to reappear.<br />

Rogue domain name registrars have been pinpointed<br />

as a problem. What do they have to do before selling<br />

a domain? What can brands do?<br />

large amount of attempts with different cards before a payment is<br />

successful. If a couple of such ‘warning’ boxes are ticked, we will<br />

not simply process the request automatically but first carry out a<br />

manual verification.<br />

This means that a very small number of legitimate registrations are<br />

slightly delayed, but almost all registrations going through manual<br />

verification turn out to be clear attempts to a phishing website online.<br />

Next to that, there is not much a registrar can do before selling<br />

a domain name, but there is also lot that can be done afterwards<br />

and this is the difference between a trustworthy registrar and a<br />

rogue registrar.<br />

Because with most registrars, the registration process is fully<br />

automated, there is no easy way to verify trademark infringements<br />

up front. But if a registrar is known to instantly disable domain<br />

names that turn out to be phishing or spammers, then that registrar<br />

will be of no use to those criminals as the websites registered via<br />

such a registrar aren’t active long enough to actually use them.<br />

How should brands choose which domain names to<br />

register or block?<br />

Mortelmans: There is one golden rule: protect your brand under<br />

the country code TLDs where your clients are located.<br />

Since the introduction of the new gTLDs, for most brands it’s no<br />

longer possible to simply protect their names under every single<br />

TLD. Next to no more than a handful of large brands, such as<br />

Apple and Google, no-one is doing that any longer.<br />

If you’re selling bikes, for example, you’ll probably want your name<br />

under .bike, but you probably don’t want it under .dental.<br />

And then there are a large number of new gTLDs in between that,<br />

which only the brand holder can decide are important or not.<br />

What are the must-haves for any protection strategy?<br />

March: Brands must first establish the elements that require<br />

protection. They then need to set a realistic budget depending<br />

on the size and value of these elements, and prioritise their<br />

importance geographically.<br />

Brands can then set up tools to monitor their trademarks. They<br />

must also routinely re-asses in order to maintain their focus on<br />

what’s important.<br />

Mortelmans: Make sure you have a trusted partner for your<br />

domain name registrations that you can contact. You’ll know<br />

which regions and markets are important for your brand, but your<br />

registrar should be able to assist you with informing you about<br />

which extensions are important for that region or market.<br />

Bart Mortelmans: While it is not easy to catch criminal registration<br />

requests before they are activated in the automated registration<br />

process, we as a registrar have been able to successfully block most<br />

requests with some simple verifications. It mostly comes down to<br />

spotting strange behaviour in the order and payment process. That<br />

can be stuff such as the country from where the order is placed<br />

not corresponding with the country of the credit card, or seeing a<br />

32<br />

Pick a registrar that offers you all possibilities but doesn’t try to sell<br />

you domain names you don’t need.<br />

Make sure that the domain names you end up registering are<br />

registered in your name and try to put them to actual use. If<br />

you have the domain name, at least have it forwarded to your<br />

website. IPPro


You’ve Built Your<br />

Business & Your Brand.<br />

Now How Do You Secure & Protect It?<br />

Corporate Brand Services<br />

The success of an effective brand management strategy is<br />

finding a comprehensive brand protection partner who is<br />

flexible enough to meet your needs, offers worldwide<br />

coverage, and is available within your budget.<br />

Our Corporate Brand Protection Services do just that.<br />

101domain has built its reputation on providing solid and<br />

tested corporate domain name management services and is<br />

a leading expert in the world of domain names.<br />

Corporate Brand Services<br />

We Offer...<br />

Trademark Clearinghouse Services<br />

Corporate Domain Name Management<br />

• Sunrise & Landrush Services<br />

• Renewal & Consolidation Services<br />

• gTLDs, ccTLDs, and new gTLDs<br />

• Trustee/Local Presence Services<br />

• Robust Security Features<br />

Monitoring Services<br />

• Global Domain Names<br />

• Social Media<br />

• Paid Advertising<br />

Flexible Billing Options<br />

Dedicated Account Managers<br />

US 888.982.7940 • Int ++1 760.448.2394 • www.corporate.1 0 1 domain.com<br />

© 2013 101domain, Inc.


Deciding when to decide<br />

The lessons learned from the AIA aftershock prove that ongoing<br />

cooperation and partnership is the best way to achieve an<br />

organisation’s goals, says Matthew Sekac of Park IP Translations<br />

As predicted, the first half of 2015 saw many in the patent industry<br />

preparing for a historic spike in US-originating patent applications<br />

that were due for Patent Cooperation Treaty (PCT) national phase<br />

entry on or near 15 September 2015.<br />

This was the consequence of an industry-wide rush to get new<br />

applications on file before the rule changes in the America Invents<br />

Act (AIA) went into effect on 16 March 2013. In early 2014, Park<br />

34<br />

IP Translations began sharing and preparing for this phenomenon<br />

and its potential impact on the volumes of translation requests,<br />

which we entitled The AIA’s Foreign Filing Aftershock.<br />

The forecast received widespread attention across the industry,<br />

including patent practitioners, trade publications and other<br />

professional service providers. These historic circumstances<br />

introduced a potential risk for patent applicants and language


PatentTranslations<br />

“<br />

Planning in advance provides the opportunity to build in a<br />

comfortable buffer of time to ensure that unforeseen circumstances<br />

do not have damaging consequences. Extra lead-time makes it<br />

possible to implement a process with multiple checks that reduce risk<br />

”<br />

Matthew Sekac, Senior director of strategy, Park IP Translations, a Welocalize company<br />

service providers around the world. Any provider that did not start<br />

to prepare well in advance would create unnecessary risk and<br />

potential financial losses for patent owners and legal practitioners.<br />

The campaign to educate the market and clients started in 2014,<br />

however, it stands to have a lasting impact on the patent and patent<br />

translation industries. The bar has been set on how legal professionals<br />

and language service providers must work together to ensure that<br />

source of risk are identified early, requirements are understood, and<br />

potential roadblocks or challenges are communicated and prepared<br />

for well in advance. Constant communication, open feedback and<br />

trusted partner values do matter and can avert hazardous outcomes.<br />

Findings based on experience<br />

Direct customer experiences and business intelligence obtained<br />

throughout the spike provided an enormous amount of valuable<br />

data about how our clients work and what their processes look like<br />

for making foreign filing decisions.<br />

We were surprised at how widely approaches varied for both law<br />

firms and corporations. Some were rigidly organised, timely and<br />

efficient in their approach, while others were ad hoc, inconsistent<br />

and usually last-minute.<br />

What we also found, less surprisingly, was that while the first<br />

group of clients was readily able to take action and make<br />

adjustments, the second group, while receptive to the information<br />

and in agreement with our conclusions, struggled to alter or<br />

accelerate internal practices.<br />

For example, in a discussion with a patent paralegal at a large patent<br />

filing organisation, there was natural agreement that the best course<br />

was to act quickly. Unfortunately, they also expressed scepticism<br />

that anything could be done to get filing decisions sooner.<br />

The sentiment was that it made perfect sense to start early and<br />

they appreciated the guidance and education, but it’s just too hard<br />

to change the way things normally get done.<br />

35<br />

In a 2015 survey, Park IP Translations asked a large sample of<br />

patent professionals how much lead time they normally had to work<br />

with when doing a foreign filing. More than half of respondents<br />

reported that foreign filing decisions were made and instructions<br />

sent less than 30 days before the applicable deadline for any given<br />

application. A very small minority, only 2 percent of respondents,<br />

reported they had 90 days or more of lead time.<br />

An analysis of data on Park IP’s filing translation projects<br />

corroborates these findings. The data reveals that most patent<br />

professionals are instructed less than 30 days before the applicable<br />

filing deadline, and at least for our casework, roughly one third are<br />

instructed less than two weeks in advance.<br />

Preparing for the inevitable<br />

Understanding the circumstances under which patent professionals<br />

operate is critical for patent service providers. Experience and data<br />

on timing and deadline requirements must be part of the basis for<br />

developing sustainable and effective service offerings that cater to<br />

the needs of the client.<br />

When it comes to foreign patent filings, there is some cushion built<br />

into the system. It is helpful that most PCT countries have grace<br />

periods available for submitting translated applications after the<br />

initial filing deadline. For many organisations, utilisation of these<br />

extensions has become routine practice.<br />

When additional time is not available, scale from service providers<br />

is critical. As an example, Park IP Translations has the flexible<br />

capacity and the process expertise to organise and deploy large<br />

teams of resources capable of executing very large volumes in<br />

very short timetables.<br />

Scaling capability is essential for helping clients out of some tight<br />

spots. Park IP Translations has been able to deliver translated<br />

materials under extremely challenging conditions for filing around<br />

the world because of a robust, scalable operational infrastructure<br />

and extensive experience managing rush projects. Sometimes this


PatentTranslations<br />

requires imagination and will, as in one particular engagement<br />

where the final product was hand delivered to a patent professional<br />

about to board a plane bound for another continent, with a filing<br />

deadline mere hours after the flight’s scheduled landing.<br />

These situations are not unmanageable, but they are also not<br />

ideal. Once filing decisions are made, the process of foreign filing<br />

a patent application requires the contribution of multiple parties.<br />

The client initiates and oversees the process, often with the help<br />

of outside counsel or another service provider, and executes the<br />

required documentation. Translators prepare required translations.<br />

Then patent agents prepare the filing documents and submit them<br />

to the patent office with the support of their own staff.<br />

Almost everyone with a role to play in that filing process will be<br />

used to doing their part under pressure—and often routinely.<br />

That’s just how business gets done in many cases. Unfortunately,<br />

this also creates risk. Deadline pressure simply constrains the<br />

ability of all parties to perform their role with maximum care, and<br />

frequently generates additional expense.<br />

It negates the possibility of building in buffers of time to<br />

accommodate unforeseen circumstances. However adept we<br />

have all become at managing these unplanned circumstances,<br />

these conditions simply increase the likelihood of mistakes. And<br />

in this business, even small mistakes can be very costly.<br />

Plan ahead to get ahead<br />

There are any number of reasons why organisations start the foreign<br />

filing process close to the deadline. Foreign filing decisions often<br />

have significant budgetary impact, especially for organisations<br />

such as small biotechnology companies that might need to go out<br />

and raise more than $100,000 just to apply for patent protection in<br />

a half dozen foreign countries.<br />

from some structural advantage. It should be noted that they come<br />

from organisations both big and small across a diverse array of<br />

industry sectors. Their real source of success is the series of<br />

proactive initiatives they have undertaken to improve internal<br />

procedures for managing their foreign patent filings.<br />

Decide now, wait later<br />

It’s as simple as it is daunting. Organisations that act in advance<br />

are predominantly the organisations that choose to act in<br />

advance—and then follow through. Make no mistake, they benefit<br />

from it. These organisations don’t rack-up late filing charges and<br />

they avoid fees for expedited services.<br />

By starting the conversation early, they can gather information<br />

from service providers and other partners to inform their budget<br />

impact assessments.<br />

Planning in advance provides the opportunity to build in a comfortable<br />

buffer of time to ensure that unforeseen circumstances do not have<br />

damaging consequences. Extra lead-time makes it possible to<br />

implement a process with multiple checks that reduce risk.<br />

These are also the organisations that have the easiest time<br />

avoiding risk from sudden spikes in volume requirements, whether<br />

the source is internal or exogenous. The lessons learned from the<br />

AIA aftershock prove that ongoing cooperation and partnership is<br />

the best way for all to achieve their respective goals—on time and<br />

in all languages. IPPro<br />

Understanding the costs is part one of the planning process. The<br />

precise expenses over time may not be clear to decision makers,<br />

which can complicate the cost-benefit analysis and obstruct efforts<br />

to assess the relative priority of applications within a limited budget.<br />

These decisions also frequently require the participation of multiple<br />

stakeholders from different departments, or they might depend on<br />

the results of an incomplete study or other ongoing research.<br />

In many cases, the biggest reason is simply institutional inertia.<br />

Information collected by Park IP Translations in preparing clients<br />

for the AIA spike in 2015 suggests that frequently the only barrier to<br />

starting the foreign filing process early is the ‘get started’ meeting.<br />

At many organisations, the meeting does not usually happen until a<br />

month before the filing deadlines, and not for any particular reason.<br />

Most of the filing decisions are actually pretty straightforward. As<br />

one department head recently suggested: “The filing decisions<br />

on most of our applications that are already made, they’re just in<br />

peoples’ heads.” And the process cannot get started until what is<br />

‘in peoples’ heads’ is formally discussed and put on paper.<br />

Why is it normal to wait until the last 30 days? The most common<br />

response from the groups we have talked to is simply that “they<br />

have always done it this way”. There are many patent professionals<br />

that are almost unfailingly diligent about instructing new foreign<br />

filings well ahead of the applicable deadlines. Perhaps they benefit<br />

36


VOTED<br />

No. 1<br />

You can access WebTMS anywhere you have an Internet connection and on any device,<br />

e.g. Laptop, Macbook, PC, Apple Mac, Tablet, Smartphone (all brands).<br />

The whole team is dedicated to the WebTMS software only, anyone who picks up the phone will<br />

be able to help. Unlimited technical support via telephone and email is part of the service.<br />

WebTMS is very intuitive and user friendly without sacrificing power or functionality.<br />

The WebTMS team have been creating, developing and supporting the WebTMS software for 17<br />

years, including data migration and conversion.


Perfecting patents<br />

Experts discuss how best to translate a patent, and what to look for in a partner


Translations101<br />

Caroline Chenique<br />

Group business development director<br />

RWS Group<br />

Matthew Sekac<br />

Senior director<br />

Park IP Translations<br />

Maria Nilova<br />

Managing partner<br />

Patentica LLP<br />

Ina Bjerre Larsen<br />

Partner<br />

Zacco<br />

Sergey Sokolov<br />

Key translation specialist<br />

Patentica LLP<br />

Mark Dugdale<br />

Editor<br />

IPPro The Internet and Life Sciences<br />

What is the demand like for patent translations compared<br />

to a decade ago?<br />

Caroline Chenique: The number of patent applications has increased<br />

over the last decade and with it the number of international filings<br />

requiring translations. Looking at European patent applications<br />

between 2005 and 2014, numbers have increased by 18 percent,<br />

climbing from 128,665 in 2005 to 151,981 in 2014. The figures<br />

from the World Intellectual Property Organization (WIPO) show an<br />

even more dramatic increase with Patent Cooperation Treaty (PCT)<br />

national phase entries in the world shooting up by 93 percent from<br />

292,800 in 2003 to 565,500 in 2013.<br />

Today, the demand for translations remains strong. The number<br />

of US and European filings in Asia has increased vastly in<br />

the last 10 years, coupled with the soaring number of patent<br />

applications coming out of China. RWS Group has been active in<br />

China and Japan for many years with large teams of translators,<br />

checkers, project managers and business developers based<br />

in our Tokyo and Beijing offices catering for both foreign and<br />

domestic clients.<br />

But it is not only the numbers of patents being filed that is affecting<br />

demand, but also patent legislation. The America Invents Act (AIA)<br />

gave patent owners much to consider. The switch from first-toinvent<br />

to first-to-to file in March of 2013 is still a challenge felt by<br />

applicants as they rethink how to approach their filing strategies.<br />

At the moment, there is a spike in the demand for translations due<br />

to the very large number of cases filed before the AIA came into<br />

force and that are due to enter the PCT national phase. We are well<br />

equipped to deal with this increase, but obviously the earlier our<br />

clients place their orders the better.<br />

In Europe, upcoming changes associated with the unitary patent<br />

is the main topic concerning professionals. Once the agreement is<br />

officially implemented, a significant change in how to file throughout<br />

Europe will be felt. That said, we don’t anticipate such an immediate<br />

effect on translation demand as the London Agreement had in 2008,<br />

where in certain countries translation requirements were minimised<br />

or waived.<br />

39<br />

Maria Nilova: Based on our practice, demand for patent translations<br />

has grown exponentially. Nowadays, many companies, from small<br />

start-ups to multinational corporations, are becoming extremely<br />

concerned about cost efficiency while wanting high quality services,<br />

in particular for patent translations. Traditionally, an applicant keen<br />

to obtain patent protection in a foreign country would fully delegate<br />

all prosecution, including preparing a patent translation, to a local<br />

patent agent. While no-one doubts the quality of this approach,<br />

it is well known how expensive this could be, especially in cases<br />

of multi-country national entries, which are common not only for<br />

multinational businesses but also emerging and promising new<br />

technologies. In all of these cases, it is of primary importance to<br />

provide high quality, affordable patent translations. That is why in<br />

roughly 30 percent of cases, applicants opt for a translation agency<br />

rather than a patent firm.<br />

Matthew Sekac: Demand has grown considerably since 2005.<br />

Trends in demand for patent translations are driven predominantly<br />

by trends in international patent filings, and the trend over the past<br />

decade has been consistent growth. For example, statistics available<br />

from WIPO indicate that PCT national phase entries in non-English<br />

speaking jurisdictions grew by nearly 50 percent between 2005 and<br />

2013 (the most recent year for which data is available).<br />

The data suggests an increasingly global economy with international<br />

organisations focused on developing and protecting their IP on an<br />

increasingly broad scale, with developing economies playing an<br />

increasingly important role in global IP strategies. Between 2005<br />

and 2013, national phase filings in lower and upper middle-income<br />

countries grew by 80 percent. Filings grew by 59 percent in Asian<br />

countries and 57 percent in Latin America and the Caribbean. Trends<br />

such as these are major contributors to the growth in demand for<br />

patent translations.<br />

Another important trend in the market has involved an increasing<br />

level of attention being paid to patent translations, by Western<br />

patent practitioners in particular. Historically, translation fell within<br />

the (nearly) exclusive domain of foreign patent agents. This is an<br />

unavoidable peripheral expense—a single, off-the-radar line-item<br />

buried in a sea of invoices, which was just been part of the cost of


Translations101<br />

doing business. More and more organisations are now taking a hard<br />

look at line-items such as translation and realising how dramatically<br />

they can add up to growing expenses.<br />

Beyond cost analysis, the internet makes it possible to build a global<br />

network of qualified resources that were once accessible only to<br />

local patent firms in each country. This creates an opportunity for<br />

global organisations to consolidate their translation needs through<br />

dedicated service providers with centralised operations, legal<br />

expertise and uniform quality assurance systems. The result is<br />

improved international patent quality and reduced cost of ownership.<br />

very sophisticated business niche in the coming years due to<br />

growing demand in professional patent translations. Unfortunately,<br />

there are few, if any, educational facilities for patent translation in<br />

Russia to teach the confluence of jurisprudence, linguistics, and a<br />

relevant applied science.<br />

Sekac: From a macro viewpoint, the talent pool in this area appears<br />

mostly adequate to accommodate demand. Generally speaking, the<br />

work is getting done. One important feature of this market niche is<br />

that the aggregate supply of patent translator man-hours is not as<br />

fixed as in other areas.<br />

Ina Bjerre Larsen: The overall volume of straightforward patent<br />

prosecution translations (such as application texts for national<br />

filing) has definitely decreased compared to a decade ago—and<br />

probably will in the future, too, due to the unitary patent and general<br />

harmonisation. However, since the market for IP translation services<br />

has changed immensely, the demand for IP-related translations<br />

continues to be high. this relates to IP litigation, opposition, and<br />

mergers and acquisitions and other transactional translations that<br />

originate in our clients’ respective business environments, including<br />

domain names and trademarks.<br />

What is the talent pool like in this area? Are more<br />

bodies needed?<br />

Sergey Sokolov: The market for patent translation in Russia and the<br />

Commonwealth of Independent States countries, including Ukraine,<br />

is immense. Based on our experience, workable high quality patent<br />

translations come from patent firms. General practice translation<br />

agencies in our region, even well renowned ones, generally cannot<br />

satisfactorily cope with patent translation, especially in languages<br />

other than English.<br />

Our translations are hand-made through a three-stage process,<br />

therefore developing a ripe product. We presume other patent firms<br />

follow the same routine. We suppose that translation agencies<br />

specialising in patent translations would create an excellent and<br />

40<br />

To accurately render the complex technical material contained in<br />

patent applications, translators must have an advanced level of<br />

competency in their field. They need to be experts. Much of the<br />

work in other translation industry segments is done by professionals<br />

who are translators by trade. Many of the best patent translators are<br />

also researchers, technicians, technical or scientific consultants for<br />

patent firms, or work as patent examiners or even patent agents.<br />

The result is a certain flexibility in the overall supply that can help<br />

absorb fluctuations in demand.<br />

I should emphasise that while many patent translators do not<br />

dedicate their entire work day to translation, they are no less<br />

capable as a result. On the contrary, active professional activity<br />

within their field serves to strengthen, reinforce and maintain their<br />

ability to absorb and engage the material they translate.<br />

There is a trade-off. Skilled patent translators sometimes resist the<br />

use of technology or updated methodologies that require an initial<br />

investment of time to learn. If the worldwide pool of patent translators<br />

has any notable shortcoming, it would be defined as a certain<br />

reluctance to modernise. For patent translation organisations,<br />

technology will be increasingly important to quality and capacity<br />

management as demand continues to grow. This includes an<br />

evolving suite of CAT (computer-aided translation) tools, workflow<br />

management systems, and other productivity-enhancing technology<br />

that requires utilisation by translators to achieve its potential.


THE BEST WAY<br />

TO PREDICT<br />

THE FUTURE<br />

IS TO INVENT IT.<br />

Alan Kay<br />

Whether a fledgling startup,<br />

established SME or<br />

multinational, whatever your<br />

invention, technology or brand,<br />

we will help you get and keep<br />

the best protection for it.<br />

+44 (0)20 7269 8550<br />

mail@dyoung.com<br />

www.dyoung.com


Translations101<br />

We have made great progress on this front through proactive<br />

engagement, support, and well-funded training initiatives. We are<br />

prepared, equipped and excited about the future.<br />

Larsen: Given the Zacco patent translation team’s history—we<br />

actually grew after the London Agreement in Denmark/Sweden<br />

and gained valuable experience in handling the same situation<br />

in Norway, while others downscaled their translation businesses<br />

considerably, or shut them down altogether. We are fortunate that,<br />

today, we employ the best IP translator pool in Scandinavia with a<br />

huge amount of combined experience and skill.<br />

They are a highly adaptive and resilient team and they work<br />

extremely efficiently with state-of-the-art tools. The resilience of<br />

the Zacco translators to changes in the IP services market enables<br />

us to cover current needs quite well—even to the extent that, in<br />

principle, we deliver from day-to-day or even on the same day for<br />

validation translations.<br />

However, our business develops constantly—due to changes in the<br />

IP environment, but also due to changes in the businesses whose IP<br />

Zacco handles, so new talent is generally always in demand here.<br />

Chenique: We’re always on the lookout for new translators and there<br />

are frequently opportunities to join our in-house team as well as to<br />

become one of our freelance staff.<br />

We are quite unique in the patent translation business with a large<br />

team of translators based in our offices, in addition to a network of<br />

freelancers backed by our team of in-house linguists who are tasked<br />

with the word for word checking of translations. We certainly think<br />

that more patent translators and checkers are needed, but it’s tough<br />

to recruit the people who meet our exacting standards.<br />

Linguistic competency: a basic requirement for any type of translation.<br />

Patent translators must have advanced competency in at least two<br />

languages, and should only work into their native language.<br />

Technical competency: in order to completely and accurately<br />

render the meaning and intent of a patent application in another<br />

language, it requires expertise in the technical field of the invention.<br />

The best patent translators often have additional experience working<br />

as lab technicians, researchers, engineers, patent attorneys, agents<br />

or patent examiners.<br />

Patent-specific competency: translators also require a firm grasp<br />

of the complex and nuanced language used by patent practitioners.<br />

Patent applications are extremely demanding legal instruments that<br />

are structured carefully in light of a specific set of rules and conventions<br />

governing the legal impact of particular terms and formulations.<br />

It’s not sufficient to know the language and know the technology.<br />

Patent translators must also understand the nuanced language of<br />

patent law to accurately and completely render their source text.<br />

Larsen: First and foremost, the perfect patent translator must be<br />

acutely aware of his/her responsibilities as to the maintenance and<br />

safeguarding the IP rights of any Zacco client.<br />

This means that, apart from the obvious master’s degree in business<br />

languages, he/she must know IP well enough to provide exactly what<br />

the Zacco client needs at any point in time, be it translations for litigation,<br />

In China, for example, we’ve put a programme in place to work<br />

very closely with several local universities. We take on interns<br />

who receive onsite training and who, if they are successful, go<br />

on to join our team. It’s proving a very effective way to recruit<br />

and train our staff in China and to meet the high demand for<br />

translations into Chinese.<br />

What skills must the perfect patent translator possess?<br />

Sekac: Patent translators are human beings, so none will ever be<br />

perfect. The best patent translators make the fewest mistakes. They<br />

also have the skills, credentials and specialised expertise necessary<br />

to avoid the worst kind of mistakes. For patents, these are mistakes<br />

that materially affect patentability, the scope of coverage, or the<br />

viability of enforcement.<br />

These errors are usually the result of a translator’s failure to fully<br />

grasp the nature of the technology or the application’s carefully<br />

structured language.<br />

The most successful patent translators have years of experience.<br />

We normally require at least six years of experience translating<br />

patents within a particular technical field. They are proficient users<br />

of an array of scientific information resources, such as technical<br />

dictionaries and glossaries.<br />

“The law is reason unaffected by desire.”<br />

patents<br />

trademarks<br />

designs<br />

domains<br />

life sciences<br />

unfair competition<br />

data protection<br />

www.germus.hu<br />

They should possess three distinct layers of advanced competency,<br />

which are critical to accurately translating patent language:<br />

42


Translations101<br />

filing, or for information only, and he/she must always be acutely aware of<br />

reliability in delivery and quality.<br />

The application of a linguistic mindset in combination with business<br />

awareness is absolutely imperative to providing quality and creating<br />

value in an IP environment.<br />

Nilova: First and foremost, a technical background in at least one of<br />

the professional areas, such as mechanics, electronics, chemistry,<br />

pharmaceuticals and biotechnology.<br />

Secondly, a translator needs industry- or scientific-experience, as well as<br />

any practice that provides a general understanding of the professional<br />

language and its usage. Every professional area has its own jargon.<br />

Thirdly, a profound knowledge of patent terminology is needed, as<br />

is a good understanding of the general structure of both a patent<br />

application and legislative regulations in different countries, as well<br />

as patent language nuances.<br />

Chenique: The perfect patent translator is quite a rare bird as he or she<br />

must be a subject specialist, with a degree in engineering or in science<br />

in order to be able to understand and translate the technologies that our<br />

clients cover in chemistry and life sciences, electrical, electronics and<br />

physics, mechanical and engineering.<br />

In addition to their technical qualifications, our translators also<br />

obviously have to be linguists capable of translating a foreign<br />

language into their mother tongue.<br />

Trim: 92(W) x 120mm (H)<br />

The third prerequisite is to be able to translate the source text as<br />

drafted, to comply with the specificities of patent language, and most<br />

importantly, to translate without either broadening or narrowing the<br />

scope of the patent.<br />

Ultimately, though our translators are a key part of a team of<br />

professionals who ensure that our clients receive only the highest<br />

quality, we have the following systems in place to ensure quality:<br />

ISO 9001-certified procedures with proofing of all translations by<br />

a checker; project managers troubleshooting for any potentially<br />

unclear terms in the source text; and ensuring compliance of<br />

translations with the specifications of local patent attorney firms and<br />

the national patent offices.<br />

The quality of a translation can make or break a patent<br />

application—but how are you keeping costs down<br />

without compromising on quality?<br />

Sokolov: Our experience shows this can be achieved through our<br />

three-stage process. Firstly, by employing highly educated exindustry<br />

professionals with a profound knowledge of the profession,<br />

keeping in mind today’s inventions deal with cutting edge<br />

technologies. They do the primary translation.<br />

Secondly, by training professional patent agents having very good<br />

native language skills and possessing good knowledge of patent<br />

terminology. They do the proofreading of the primary translations.<br />

Thirdly, by having a patent attorney review the claims. As a result,<br />

we differentiate between industry knowledge and patent skills,<br />

combining them and taking the best of both worlds.<br />

Less work would definitely mean compromised quality. We realise<br />

that compromised quality cannot be permanently sold as a firstrate<br />

product. When under pressure we focus on vital parts of an<br />

application to still provide the best possible solution within the<br />

constrained budget or restricted timeframe.<br />

Larsen: Obviously, this aspect became increasingly important<br />

during the recent financial crisis—everybody was affected by this.<br />

Translation is now a commodity and it is consequently subject to<br />

fierce competition.<br />

However, it is imperative to keep in mind that the quality of a<br />

translation can make or break an IP right. It goes without saying<br />

that we cannot compromise on quality and delivery, but at Zacco<br />

we apply an overall very cost-conscious mindset that allows us to<br />

operate quite well in our segment, which is not a discount segment<br />

as we truly believe in the value created by our unique IP product<br />

and our unique IP competences.<br />

An example of this is that we find it very important to also give full<br />

attention to the source text and to report on anything that seems<br />

amiss—a service that is included in our translation fee and which<br />

will, obviously, save money in the long run. IP competence and<br />

translation skills combined may greatly reduce the costly fuss that<br />

might otherwise occur.<br />

43<br />

We also do our utmost to ensure that Zacco clients get exactly<br />

the product they request—to allocate the correct resources staffwise<br />

and time-wise. A translation order is always analysed before<br />

embarking on the job, to identify the intended IP use and what


Translations101<br />

resources are needed to reflect the value of the translation to<br />

our client and to safeguard the scope of its rights. If in doubt, we<br />

ask. Finally, Zacco’s internal handling and administration is at a<br />

minimum, since the Zacco team can deliver within all combinations<br />

of the official European patent and Scandinavian languages.<br />

Chenique: Having our own team of translators in combination<br />

with a network of tried and trusted freelancers who receive high<br />

volumes of work from RWS has been instrumental in ensuring we<br />

not only offer the highest quality, but also are cost-effective.Our inhouse<br />

tools and systems also boost productivity and quality. RWS<br />

Group’s own patent database, PatBase, for example, ensures<br />

that our translators use the most appropriate terminology for a<br />

particular applicant or field.<br />

In addition, streamlined work flows, centralised project management<br />

and leading edge translation technology are all factors that enable<br />

us to provide the top quality for which RWS Group is renowned, as<br />

well as competitive pricing. Our clients face relentless pressure on<br />

their costs and we have to constantly find new ways of guaranteeing<br />

quality and delivering additional economies.<br />

The end-to-end solution that we now offer for foreign filing, thanks<br />

to our acquisition of inovia, the world’s number one filing platform<br />

for PCT national phase entries, is an example. Together with inovia<br />

we bring our clients the best in patent translation combined with the<br />

best in filing, and all for a great price that is difficult to beat.<br />

Sekac: Scale is one of the straightforward ways to keep costs<br />

down without compromising quality. At Park IP Translations, we<br />

have been very successful at leveraging our growth to build a lean<br />

and robust production infrastructure. We have established strong<br />

relationships with capable and reliable partners, affording us<br />

dedicated and flexible capacity with room to grow further. We<br />

have also negotiated competitive buy rates that reflect our<br />

volume without putting our partners in a compromising position.<br />

Ultimately, keeping costs down without compromising on quality<br />

means prioritising quality. Volume gives you leverage over your<br />

suppliers. They will go a long way to avoid losing your business, if<br />

they depend on it. We have found that the best partnerships are truly<br />

partnerships—mutually beneficial relationships that can be counted<br />

on to serve their purpose.<br />

Technology is also key, such as translation memory (TM). When<br />

used effectively, TMs can significantly boost translator productivity<br />

and generate escalating cost savings as the database of translated<br />

material is built up over time.<br />

Patents don’t offer the biggest opportunity for leveraging previously<br />

translated material, however, it does help in some cost savings. TMs<br />

can also improve quality by streamlining terminology management<br />

and improving the consistency of translated language.<br />

Technology drives every facet of our process. We have a talented<br />

team of full-time developers that allows us to really empower<br />

imagination. We have developed cutting-edge tools for measuring<br />

productivity, managing quality, forecasting, interacting with clientside<br />

users and systems, and automating production workflows.<br />

These tools make our services smarter, with lower costs, at higher<br />

quality levels, and with data to back it up. IPPro<br />

44


J. Varbanov & Partners<br />

European and Bulgarian Patent & Trademark Attorneys<br />

One of the oldest and leading IP companies in Bulgaria<br />

Professional, cost effective services and quality advices<br />

Areas of practice:<br />

*IP Protection<br />

*IP Enforcement<br />

*Anti-counterfeiting<br />

*Litigations<br />

*Domain name registrations<br />

*IP watches<br />

PO Box 1152, BG-1000 Sofia, Bulgaria<br />

South Park Complex, bl.1A, 2nd fl., BG-1421, Sofia, Bulgaria<br />

Tel.: (+359 2) 986 51 25, Fax: (+359 2) 980 32 47,<br />

e-mail: jvp@jvpatents.com<br />

www.jvpatents.com


BigInterview<br />

Bob Stembridge<br />

Senior analyst<br />

Thomson Reuters IP & Science<br />

Lawrence Liberti<br />

Executive director, Centre for<br />

Innovation in Regulatory Science<br />

Thomson Reuters<br />

Dr Kirk Gallagher<br />

Partner<br />

D Young & Co<br />

Mark Dugdale<br />

Editor<br />

IPPro The Internet and Life Sciences<br />

Who will be developing the next new drugs and therapies,<br />

and in what areas will these innovations happen?<br />

Bob Stembridge: We do have quantitative ways of showing which new<br />

drugs and therapies will be making a big impact on the market. Our<br />

recent 2015 Drugs to Watch report highlights 11 potential blockbuster<br />

drugs that we forecast to earn more than $1 billion by 2019. It’s set to<br />

be a massive year with eight more blockbuster drugs expected than in<br />

2014. It’s leading some commentators to raise the question of whether<br />

we are seeing a renaissance in big pharma.<br />

According to the figures from earlier in 2015, drugs predicted to pass the<br />

$3 billion mark with 2019 sales forecasts include: Bristol-Myers Squibb<br />

and Ono Pharmaceutical’s melanoma drug Opdivo (nivolumab) at $5.68<br />

billion; Regeneron Pharmaceuticals and Sanofi’s Praluent (alirocumab)<br />

for hypercholesterolemia at $4.41 billion; and Novartis’s Entresto (LCZ-<br />

696) for chronic heart failure at $3.73 billion.<br />

In terms of innovative areas, new advances are happening in<br />

immuno-oncology, a rapidly evolving field for drug development.<br />

The aforementioned Entresto from Novartis represents a first-inclass<br />

heart failure drug that has recently received Food and Drug<br />

Administration (FDA) approval. Other trends include innovation in<br />

treating cholesterol and the entry of more convenient all-oral regimes<br />

for hepatitis C virus.<br />

Simultaneous to all this is the rise of biosimilars. Although it is not an<br />

exact copy, a biosimilar is highly similar to an approved biologic and<br />

is developed on a designated biosimilar regulatory path. While the<br />

world’s first official biosimilar was approved by the EU back in 2006,<br />

it has taken up until March 2015 for a biosimilar to receive regulatory<br />

approval in the US.<br />

There are many players innovating in this area, with Pfizer, Eli Lilly,<br />

GlaxoSmithKline, Amgen, Biogen Idec, Merck and Sanofi among<br />

those entering the biosimilar space. A few are doing it on their own,<br />

some are partnering, and others are investing in joint ventures or<br />

biosimilar developers. They see biosimilars as a new revenue stream<br />

to help offset losses for blockbuster drugs and biologics that recently<br />

have come off patent.<br />

Kirk Gallagher: For some time now, big pharmaceutical companies have<br />

been increasingly looking to smaller biotechs, start-ups and academic<br />

departments to provide innovation in the life sciences. The smaller<br />

organisations are often better positioned to undertake highly specialised,<br />

higher risk research that may prove disruptive in a particular field.<br />

However, they are less well financed and remain reliant on the larger,<br />

more established pharma companies to fund the later stages of drug<br />

development and clinical trials. This dynamic environment has resulted<br />

in an increasing number of collaborations and licensing deals, with many<br />

acquisitions taking place around particularly promising technologies.<br />

Hot areas for innovation at the moment include immune-based therapies,<br />

where the body’s own immune system is harnessed to fight diseases<br />

such as cancer (immuno-oncology) and which may prove to be curative<br />

for previously intractable fatal or chronic diseases.<br />

In addition, gene therapy is beginning to fulfil its promise despite<br />

significant early setbacks that many thought would completely undermine<br />

the field. Gene therapy is a powerful therapeutic approach that enables,<br />

for example, the editing or deletion of defective genes in an organism, or<br />

the introduction of new genes to provide a targeted effect. High-profile<br />

recent developments include the restoration of vision in patients with<br />

previously incurable hereditary diseases.<br />

Cell-based therapies, such as stem cell therapy and autologous cell<br />

therapy, are also becoming more prevalent. Autologous approaches are<br />

advantageous, because a patient’s own cells are removed, treated and<br />

then transplanted back, which avoids the risk of provoking an immune<br />

response. Notably, these cell-based methods often draw heavily on gene<br />

therapy approaches and may find utility in treating neurodegenerative<br />

diseases such as Parkinson’s, or spinal cord injury.<br />

Significant breakthroughs have also been made in gene editing<br />

techniques, which further increase the power of gene therapy as a whole.<br />

Using new editing technologies, DNA may be precisely inserted, replaced<br />

or removed from a genome using artificially engineered nucleases such<br />

as transcription activator-like effector nucleases (TALENs) and the<br />

CRISPR/Cas system. These approaches show promise for the treatment<br />

of diseases such as HIV and sickle cell disease, and prevention of<br />

mitochondrial disease by destroying mutant mitochondria.<br />

Another advantage is that biosimilars are offered at lower prices than<br />

the original. Remsima, an infliximab biosimilar, is famously almost 70<br />

percent cheaper in Norway. Reduced pricing means that biosimilars can<br />

be available to more patients than the original, expensive biologics ever<br />

could and is a great benefit to healthcare providers in many countries<br />

that are under ever-increasing financial strain.<br />

47<br />

How well positioned are IP systems around the world<br />

to encourage innovation in these areas?<br />

Stembridge: Pharmaceutical research has always been a costly and<br />

risky business. A Tufts Center for the Study of Drug Development<br />

report, issued in November 2014, indicates that after discovery and


development of a drug, it now often takes more than a decade to gain<br />

marketing approval at an estimated cost of over $2.5 million. But that<br />

is but a fraction of the overall average cost of getting a drug from labtop<br />

to patient at an eye-watering estimated $359 million, according to<br />

the California Biomedical Research Association. Add to this that only 10<br />

percent of candidates make it to human testing, and only one in five of<br />

these are ever approved for human usage, and the business risk is clear.<br />

Global intellectual property systems are designed to address this risk by<br />

enabling sufficient protection to provide opportunity to realise suitable<br />

returns over the lifetime of the protection before drugs come off patent<br />

and generic competition ensues.<br />

As in all areas of the law, this is a difficult balance to achieve and in<br />

practice has led to some imperfections, which are in a continual process<br />

of review and adjustment to correct each swing of the pendulum.<br />

Conventional IP systems provide for patent protection of 20 years from<br />

the date of filing. Given that the total time for development and approval<br />

of a new drug is now somewhere north of 12 to 15 years, there is scant<br />

time to left realise realistic returns on investment.<br />

In recognition of this, various systems exist globally to compensate<br />

for regulatory delay and provide additional protection after expiry of<br />

the patent. In Europe, this is known as a supplementary protection<br />

certificate (SPC). An SPC normally has a maximum lifetime of five years,<br />

but that can be extended to five-and-a-half years in certain specific<br />

circumstances. SPC protection is available in all EU countries, although<br />

there is no Europe-wide registration system and application has to be<br />

made in each individual country.<br />

Equivalent systems are also available in the US (patent term restoration,<br />

providing from one to five years), Japan (five years), South Korea (up<br />

to five years) and other countries. Notably, patent term extensions for<br />

regulatory delay are not available in China and much of South America<br />

(Chile being the exception).<br />

In the area of genetic medicine, there was a period during which<br />

protection for specific genes from the human genome was available<br />

in the US, but this has effectively now been reversed by the 2013 US<br />

Supreme Court ruling in the Molecular Pathology Association v Myriad<br />

Genetics case that human genes cannot be patented.<br />

IP systems around the world continue to evolve to ensure the balance<br />

between incentivising and rewarding innovation and providing costeffective<br />

treatments for diseases globally is maintained.<br />

Gallagher: The European Patent Office (EPO) has a well-developed<br />

and relatively positive approach to innovation in these fields. As a result,<br />

it is generally possible to obtain useful patent protection covering these<br />

highly innovative technologies in Europe. Controversy does remain,<br />

however, particularly in fields that are seen by some as interfering with<br />

the fundamental mechanisms of life. Developments in jurisprudence are<br />

continually working towards balancing support of the industry, and the<br />

associated worldwide health benefits that this may bring, with potential<br />

moral and ethical concerns.<br />

A prime example relates to the patenting of stem cells. Current EPO<br />

guidelines follow the approach of the Court of Justice of the European<br />

Union (CJEU) in the Brüstle case: to be patentable in Europe, a stem<br />

cell invention should not be directed to a human embryo, nor should<br />

the subject matter of the patent have required the prior destruction of a<br />

48<br />

BigInterview<br />

human embryo at any time in the past. However, inventions relating to<br />

adult stem cells or human induced pluripotent stem cells (where adult<br />

cells are ‘reprogrammed’ to take on pluripotent capabilities so they can<br />

be used as a source of stem cells for therapeutic use) are still patentable.<br />

A more recent decision from the CJEU has clarified that parthenotes<br />

(activated unfertilised oocytes that may be used for the production of<br />

human stem cell lines) are not excluded from patentability. Although a<br />

parthenote is capable of developing into a blastocyst-like structure, it<br />

cannot develop into a human being because it lacks paternal DNA, and<br />

is therefore not considered to be a “human embryo” under European<br />

law. This decision has been welcomed by those working in the field as<br />

providing clarity on the patentability of certain stem cell types and may<br />

extend the scope of patentability in the field of stem cell research.<br />

Although not without fault, European patent practice is generally<br />

supportive of developments in the life sciences and provides reasonable<br />

certainty to applicants.<br />

In stark contrast, the US patent system is currently going through a very<br />

challenging period for life sciences applicants in the wake of the Myriad<br />

and Mayo Supreme Court decisions.<br />

The Myriad decision (June 2013), which concerned the patenting of<br />

human genes, is particularly relevant. In Myriad, the Supreme Court<br />

held that human genomic DNA is not patent eligible, because the<br />

same gene occurs in nature. However, non-naturally occurring cDNA<br />

sequences were held to be patent-eligible matter. The US Patent and<br />

Trade Office’s (USPTO) interpretation of this decision went further than<br />

this seemingly narrow finding, with the office issuing a set of guidelines<br />

in March 2014 that truly changed the fundamentals of what is patentable<br />

in the biotechnology field.<br />

The guidelines essentially excluded from patentability any naturallyoccurring<br />

substance, regardless of its isolation, purification or utility,<br />

unless it was “significantly different” to what was found in nature. After<br />

receiving a great deal of criticism, the USPTO issued revised guidance<br />

in January 2015, which somewhat reversed its position, and provides a<br />

more lenient test for patent eligibility.<br />

The new USPTO guidance first asks whether a claim is “markedly<br />

different” from a natural product. Under this test, a difference based on<br />

function, or a chemical, physical or biological property can lead to patent<br />

eligibility. Even if a claim fails this test, it may still be patent eligible if,<br />

under a second test, the claimed subject matter provides “significantly<br />

more” than a naturally occurring product. From the specific examples<br />

given in the guidance, it is clear that “significantly more” will be assessed<br />

more leniently than the approach stipulated in the previous guidance.<br />

Further guidance has just been issued (July 2015) that will hopefully<br />

provide further clarity. However, there is a still a great deal of uncertainty<br />

as to how best to obtain US patent protection for innovation in the<br />

biotechnology field, and applicants are facing serious difficulties in<br />

the prosecution of currently pending cases. This can only be seen as<br />

detrimental to technologies with the potential to revolutionise healthcare.<br />

Patent practice is developing quickly in China. However, there is<br />

generally a high burden set for life sciences applicants in providing data<br />

in patent applications at the filing stage. The Chinese patent office often<br />

requires granted claims to be limited to the reported working examples<br />

and as a consequence it can be difficult to achieve a commercially useful<br />

scope of protection based on early data. With reference to the state of


the industry discussed above, this can prove particularly problematic for<br />

small biotechs and academic applicants who may file early and in very<br />

new technologies with the aim of securing investment. Some success<br />

can be achieved by providing later data to support broader claims,<br />

however, this is an area where a more open-minded support of earlystage<br />

innovation would be beneficial.<br />

How can regulations be strengthened/relaxed to<br />

encourage innovation in new drugs and therapies?<br />

Lawrence Liberti: Timely access to safe and effective new medicines of<br />

societal value is a goal of medicine developers, regulators and payers.<br />

More flexible regulatory approaches, prompted by the need to accelerate<br />

reviews of novel HIV therapies in the 1980s, have been formalised<br />

in many jurisdictions, providing options to accelerate the regulatory<br />

review process, particularly in response to unmet medical needs. These<br />

streamlined yet robust pathways form an important part of accelerating<br />

pharmaceutical innovation.<br />

We characterise these priority and accelerated approaches as<br />

facilitated regulatory pathways (FRPs), ie, those designed to facilitate<br />

the availability, review and/or approval of medicines where there is an<br />

unmet medical need by providing alternatives to standard regulatory<br />

review routes. FRPs are increasingly commonly used in the US (for<br />

example, breakthrough therapy designation, or accelerated approvals)<br />

and growing in Japan and to some extent Europe.<br />

In this manner, drug development is expedited, and in best cases, patient<br />

access to medicines. Most recently, in the US, the 21st Century Cures<br />

Act has been designed to provide for a variety of procedures to stimulate<br />

innovation, tied in part to expedited access to important new medicines.<br />

Initiatives to investigate adaptive licensing schemes are being piloted by<br />

the European Medicines Agency (EMA) and others to characterise best<br />

practices in expediting patient access to medicines.<br />

FRPs may increase the communication and level of commitment<br />

between the developer and the agency, can give a larger role to effects<br />

on surrogate end points, and may move some of the burden of evidence<br />

generation from the pre- to the post-authorisation phase. Effective use<br />

of these modalities can improve the efficiency of the innovative medicine<br />

development process.<br />

We reviewed approvals of new active substances (NASs) by the FDA,<br />

EMA, and Japanese Pharmaceuticals and Medical Devices Agency<br />

(PMDA) between 2005 and 2014 in order to evaluate companies’ use<br />

of the different FRPs available and the role they play in expediting<br />

the approval of new medicines. Data for 825 NAS approvals between<br />

2005 and 2014 were collected from the public domain. The number of<br />

NASs approved was 281, 242 and 302 for the FDA, EMA and PMDA,<br />

respectively. Priority reviews made up 47, 7 and 28 percent of the NASs<br />

approved by the FDA, EMA and PMDA.<br />

Comparing priority with standard review approval speed, FDA priority<br />

reviews were faster (243 days) compared to the standard (456 days)<br />

in 2014. EMA priority reviews were faster (264 versus 432 days), as<br />

were PMDA priority reviews (275 versus 359 days). Therefore, in<br />

2014, the median approval times for priority reviews were very similar<br />

across the agencies.<br />

Over the last decade FRPs have played an important role, particularly at<br />

the FDA and PMDA in accelerating the approval of innovative medicines,<br />

thereby enabling treatments for diseases to be made available to<br />

50<br />

BigInterview<br />

patients in a timely manner, including orphan diseases, where little or no<br />

effective treatment options exist. The continued refinement of FRPs will<br />

contribute to innovative ways of accelerating the development of safe<br />

and effective medicines.<br />

Gallagher: As previously discussed, smaller life sciences businesses<br />

are increasingly relied on as the ‘engine houses’ of innovation.<br />

The emergence of governments that want to build science/tech hubs<br />

should be encouraged, and innovation can be strengthened by increasing<br />

tax breaks and funding opportunities for innovative businesses.<br />

The provision of improved financial support will allow small life sciences<br />

businesses to survive longer on their own before needing to find a<br />

commercial partner.<br />

This will provide vital time for the companies to develop their ideas to<br />

a sufficient extent to convince potential investors. With the increasing<br />

complexity of many modern therapeutics, more time is often vital to<br />

optimise technologies to a satisfactory level.<br />

In addition, governments and regulatory bodies need to continue to<br />

keep up with the fast pace of developments in the life sciences field. The<br />

technologies under development show vast potential, but at the same<br />

time are highly complex and may present significant safety, moral and<br />

ethical issues. Mis-regulation may result in the premature implementation<br />

of developments with adverse consequences, which may erode public<br />

trust. These complexities should not be avoided, but need to be tackled<br />

promptly and decisively.<br />

By way of example, cell-based therapies present many regulatory<br />

challenges. Despite a rich pipeline of autologous cell therapies in<br />

clinical development, to date few have made it onto the market.<br />

This may partly be because the technology faces substantial regulatory<br />

challenges. Cell therapies are highly complex products and accordingly<br />

it is difficult to assure quality and apply the same requirements as<br />

applied to a typical biologic.<br />

Furthermore, the risk of the therapies is more akin to surgeries, such as<br />

transplantations, than to a typical drug. New regulatory frameworks are<br />

urgently needed to support and ensure safety in these areas.<br />

Although not strictly regulatory, improved education of academics and<br />

small businesses in the importance of their IP would also be desirable.<br />

For example, although many academics are often keen to publish<br />

ground-breaking results as quickly as possible, if patent filings are not<br />

made in time these publications will likely jeopardise patent protection.<br />

As a result, new technologies may be neglected because investors will<br />

likely not wish to back them if others can later freely enter the market<br />

without undertaking any of the costly development work. Grace periods<br />

of a limited time frame are provided in some countries that provide a<br />

safety net against such damaging disclosures by inventors.<br />

However, these provisions are not uniform worldwide and are notably<br />

absent in Europe. Although discussions are taking place regarding the<br />

introduction of a grace period in Europe, no agreement has currently<br />

been reached. Progress in harmonising the application of grace periods<br />

would provide welcome certainty to applicants and reduce the loss<br />

of rights caused by the assumption of this safety net being available<br />

everywhere. IPPro


Named.<br />

net<br />

www.bNamed.net<br />

Easy domain name<br />

portfolio management<br />

Pr<br />

e<br />

t<br />

o<br />

c<br />

t<br />

yo<br />

u<br />

r<br />

b<br />

r<br />

b<br />

an<br />

d<br />

o<br />

n<br />

l<br />

in<br />

e<br />

Domain name specialist<br />

since 1999<br />

Competitive pricing<br />

Personal support<br />

Every possible TLD<br />

For brand owners<br />

and TM offices<br />

T: +44 20 3393 4858 info@bNamed.net<br />

T: +32 3 400 43 43 www.bNamed.net


PolandSPCs<br />

The pharmaceutical industry is a very important element of Polish<br />

economy. In 2013, the Polish pharmaceutical market was placed<br />

as the sixth among the largest markets in Europe with the annual<br />

turnover amounting to approximately €4.4 billion (IMS Health<br />

2013). Poland has also been named as one of the ‘pharmerging’<br />

markets, which by 2017 is expected to exhibit significantly higher<br />

growth rate than mature markets, such as the US, Japan, France,<br />

Germany and Spain (IMS Pharmerging White Paper, 2013), even<br />

though the pharmaceutical market value, per capita, did not<br />

exceed €115 in 2013.<br />

This economic importance of the pharmaceutical sector has also<br />

been reflected in intellectual property rights prosecution and<br />

their enforcement in Poland. Patent term extension has become<br />

one of the most important aspects of IP right protection for<br />

pharmaceuticals in Poland.<br />

Patent protection guarantees 20 years of market exclusivity for a<br />

medicinal product, covered by a patent, starting from the filing date<br />

of the patent application. The only way to extend patent protection<br />

52<br />

for a medicinal product is to apply for the grant of a supplementary<br />

protection certificate (SPC).<br />

The idea of patent term extension is relatively new in the Polish<br />

patent law system. The SPC is a protection right granted in all<br />

EU member states, including Poland, for medicinal and plant<br />

protection products based on the following EU regulations:<br />

• Regulation (EC) No 469/2009 of the European Parliament<br />

and of the Council of 6 May 2009 concerning the SPC for<br />

medicinal products, which has replaced Council Regulation<br />

(EEC) No 1768/92; and<br />

• Regulation (EC) No 1610/96 of the European Parliament and<br />

of the Council of 23 July 1996 concerning the creation of an<br />

SPC for plant protection products.<br />

This specific form of protection was also implemented in the Act<br />

of 30 June 2000 on Industrial Property Law (Journal of Laws, No<br />

119, item 1117, 2003 with later amendments) in 2002 and became<br />

a part of the Polish legal system after Poland’s accession to the<br />

EU in 2004.


PolandSPCs<br />

The SPC was introduced for medicinal and plant protection<br />

products due to the fact that the length of time of effective patent<br />

protection for these products is shorter, since they cannot be<br />

introduced into the market directly. These products can only<br />

be sold after a marketing authorisation is obtained. In order to<br />

obtain such a regulatory approval, time-consuming studies and<br />

long administrative procedures are required. These procedures<br />

significantly limit the duration of the monopoly resulting from the<br />

patent protection alone. Therefore, the SPC aims to compensate<br />

the patent owner for the lost time of patent protection.<br />

The introduction of the SPC has increased IP protection of medicinal<br />

products by awarding additional protection, which begins after patent<br />

expiry. This extra protection lasts up to five years. The protection for<br />

medicinal products resulting from the SPC can be extended even<br />

further for an additional six months (ie, paediatric extension of the<br />

SPC), however, only if specific requirements indicated in Regulation<br />

No 469/2009 and related to paediatric clinical trials are fulfilled.<br />

Many interpretational issues regarding the SPC requirements<br />

defined in Regulation No 469/2009 has been raised by different<br />

courts and authorities in EU member states. These issues resulted<br />

in abundant judgements of the Court of Justice of the EU (CJEU),<br />

whose aim has been to clarify the requirements for SPC grant and<br />

ensure their uniform application throughout the EU. Although the<br />

CJEU judgements have, in general, settled many questionable<br />

issues, they have often raised further questions regarding the<br />

53<br />

SPC and its grant conditions. This demonstrates that matters<br />

concerning the SPC are not always very straight forward and<br />

require additional explanation to accommodate new types of<br />

medications that have been recently developed.<br />

A lot of different questions are raised at the national level during<br />

the prosecution of the SPC applications by the national authorities.<br />

The Patent Office of Republic of Poland (PORP), which is the<br />

competent industrial property office for the examination of SPC<br />

applications, as well as SPC paediatric extension applications,<br />

in Poland, has developed quite an overzealous substantive<br />

examination procedure.<br />

One of the most problematic issues in Poland is the requirement of<br />

protection of the product, ie, the protection of the active ingredient of<br />

the medicinal product, by a patent in force. Of course, many aspects of<br />

this problem have already been addressed in judgements of the CJEU.<br />

However, the PORP still, somehow, manages to find new obstacles<br />

relating the scope of patent protection and thus the SPC itself.<br />

For example, in one of the recent cases, an SPC application was<br />

rejected because the basic patent, ie, the patent selected as the<br />

basis for the SPC application, referred to a chemical compound<br />

as such (without making a reference to any physical form of<br />

the compound of the invention), whereas the first marketing<br />

authorisation referred to a specific physical form of that very<br />

chemical compound.


PolandSPCs<br />

In particular, the summary of product characteristics (SmPC), a<br />

legal document approved as part of the marketing authorisation<br />

of every medicinal product, which contains information for health<br />

professionals on how to use the medicinal product safely and<br />

effectively, mentioned a specific crystalline form of the compound<br />

covered by the basic patent. Since the specification of the<br />

basic patent did not comprise any information with respect to<br />

that crystalline form of the compound of the invention, the SPC<br />

application was rejected.<br />

For the assessment of the SPC requirements, the PORP did not<br />

consider the fact that the basic patent conveyed protection for<br />

the active ingredient in any form, since it contained a product<br />

claim for the new chemical entity. However, the case has not been<br />

yet finally resolved, as an appeal has been lodged against this<br />

rejecting decision.<br />

Another issue that arises from time to time during examination of<br />

SPC applications before the PORP is the issue of the first marketing<br />

authorisation. According to current practice, the SPC application<br />

can be rejected if a similar medicinal product is already on the<br />

market, even though the PORP is unable to present the marketing<br />

authorisation for the product it juxtaposes as allegedly similar and<br />

already placed on the market.<br />

The SPC application can also be rejected if the product comprises<br />

a combination of active ingredients (A+B), and an earlier marketing<br />

authorisation for one of the products was obtained (A) with the<br />

SmPC indicating that it is possible to use this product (A) in a<br />

combination therapy with the other product (B). In this case, the<br />

PORP has indicated that a mere fact that a combination therapy<br />

is mentioned in the SmPC of an earlier marketing authoriation is<br />

enough to question the marketing authorisation for the product<br />

comprising both active ingredients A and B. However, this decision<br />

of the PORP was reversed by the Regional Administrative Court.<br />

In general, during SPC examination the PORP seems to examine<br />

criteria that do not correspond to those named in Regulation No<br />

469/2009. The PORP often refers to patentability criteria, such as<br />

sufficient support and obviousness, which should not be examined<br />

at all during prosecution of an SPC application.<br />

The problems also arise during examination of the request for<br />

paediatric extension of the SPC. Frequently, the PORP reexamines<br />

validity of the already granted SPC before it makes a<br />

decision with respect to paediatric extension. In one of the cases, a<br />

request for paediatric extension was rejected, because, according<br />

to the examiner, the SPC did not meet the transitional provisions<br />

governing the SPC grant. The PORP did not take into consideration<br />

the fact that in order to raise such an objection, the SPC should be<br />

invalidated, whereas the paediatric extension should be granted<br />

since all of the requirements for such an extension were fulfilled.<br />

Another significant problem is the requirement for too much<br />

documentation when the paediatric extension is to be granted,<br />

based on a mutual recognition procedure instead of a central<br />

EU procedure. The PORP requires copies of all marketing<br />

authorisations from all member states, including the SmPC.<br />

Moreover, the PORP can raise an objection with respect to a<br />

national marketing authorisation, if the PORP suspects that it is<br />

not the current marketing authorisation. At the same time, the<br />

PORP is not familiar with the practice of local authorities that issue<br />

the marketing authorisations in every EU member state.<br />

It is also very difficult to convince the PORP’s examiner that<br />

in the mutual recognition procedure, the statement indicating<br />

compliance with an agreed completed paediatric investigation plan<br />

will not necessarily be issued by the European Medicines Agency.<br />

Therefore, obtaining an SPC extension is much easier based on<br />

the marketing authorisation granted in the centralised procedure.<br />

Finally, it needs to be emphasised that the practice developed<br />

by the PORP with respect to SPCs has also influenced the<br />

examination of patent applications. Nowadays, the PORP very<br />

often refers to the judgements of the CJEU related to SPCs<br />

while examining the patentability of pharmaceutical inventions.<br />

Moreover, the PORP also often refers to the preamble of the<br />

SPC regulation, wherein it is indicated that all the interests at<br />

stake, including those of public health, in a sector as complex<br />

and sensitive as the pharmaceutical sector, should be taken into<br />

account. This argument is very often used to restrict the scope of<br />

protection of pharmaceutical patents.<br />

Therefore, in addition to the problematic issue that result from the<br />

SPC regulation itself, in Poland we have to deal with additional<br />

problems that are very surprising and don’t result from ambiguity<br />

these regulations, but rather from the PORP’s viewpoint that it is an<br />

authority responsible for keeping the balance between the interests<br />

of all parties, including public health and the pharmaceutical sector.<br />

However, it should be underlined that this alleged responsibility<br />

does not result from any regulations and so makes SPC and patent<br />

prosecution in Poland quite challenging. IPPro<br />

“<br />

During SPC examination the PORP seems to examine criteria<br />

that do not correspond to those named in Regulation No 469/2009.<br />

The PORP often refers to patentability criteria, such as sufficient<br />

support and obviousness, which should not be examined at all<br />

”<br />

Magdalena Tagowska, Patent attorney, Patpol<br />

54


MexicoData<br />

One fell loophole: protecting clinical data<br />

There are evident loopholes in Mexican legislation regarding IP rights<br />

and clinical data protection framed in the scope of sanitary regulatory<br />

affairs. Soledad Betanzos-Lara of Goodrich, Riquelme y Asociados reports<br />

“So, here I am. A brand new drug molecule, thoroughly researched<br />

and developed, for more than 10 years. Many monetary expenses<br />

and time investment have been put together to push me forward.<br />

I have been thoroughly clinical-trialled and proven to be safe and<br />

effective and a bunch of clinical-related data has been generated<br />

in the process. I have been named ‘the innovator’.”<br />

“Naturally, now is the time to market me, in order to reach the<br />

target patient population that I was developed for, and so, help<br />

to improve people’s health. But hang-on: before this happens, I<br />

need to go through strict sanitary regulatory approvals, qualify for<br />

intellectual property protection, and somehow secure the clinical<br />

data generated.”<br />

“Only that one thing concerns me. I’ve heard that at some point,<br />

others will try to supersede my identity with the aim of also<br />

improving people’s health, but at a lower cost than mine. And<br />

that maybe, for being approved, they will be authorised to use my<br />

clinical data. I know they call themselves ‘generics’.”<br />

“What is then out there that will secure IP and sanitary protection<br />

for me, while guarding my clinical data for the longest possible<br />

time before the entry of these generics?”<br />

This stream of consciousness, pondered by a new and innovative<br />

drug molecule—if indeed this was possible—probably depicts the<br />

fears that all innovative pharmaceutical companies have. So, how<br />

do jurisdictions protect both an innovator’s IP rights and clinical<br />

data, and maintain a sanitary regulation intelligibly linked with<br />

these, while still providing affordable and high-quality medications<br />

for the population?<br />

This is not an easy question to answer and the approaches can<br />

be diverse. The regulatory frameworks needed for intertwining<br />

IP rights, clinical data protection, sanitary regulatory affairs and<br />

access to medicines, do not exist everywhere in the world.<br />

Mexico has achieved much in this respect, although some areas of<br />

opportunity are still to be covered. IP rights protection, enabled by<br />

56<br />

the Mexican Institute of Industrial Property (Instituto Mexicano de<br />

la Propiedad Industrial, IMPI), is linked to the sanitary regulatory<br />

affairs of the Federal Commission for Protection against Sanitary<br />

Risk (Comisión Federal para la Protección contra Riesgos<br />

Sanitarios, COFEPRIS), via the so-called Linkage Gazette: a<br />

biannual publication from IMPI in which patents in-force covering<br />

allopathic medicines, second-medical uses, and formulations<br />

thereof, are disclosed.<br />

Seeking IP protection for a new molecule via patenting is standard<br />

in Mexico, as long as the patentability requirements set out by<br />

IMPI are met. Via this procedure, the innovator will benefit from<br />

20 years of protection for the active ingredient, during which, no<br />

other party can exploit the same molecule for any given purpose,<br />

being this a second medical use, a pharmaceutical composition,<br />

or a process.<br />

Simultaneously (but not always), the innovator may apply for a<br />

marketing authorisation for its drug, through the local sanitary<br />

authority. In Mexico, if the application is successful, a renewable<br />

five-year marketing authorisation for the drug will be issued.<br />

In this context, under the current Mexican legislation, a generic<br />

company may apply to COFEPRIS for a marketing authorisation<br />

for a product that falls within the scope of a patent listed in IMPI’s<br />

Linkage Gazette, within three years (for allopathic drugs and up to<br />

eight years for biocomparables) prior to the expiration date of the<br />

corresponding Mexican patent, according to the Bolar exception. It<br />

is worth noting that the marketing authorisation will not be issued<br />

by COFEPRIS until the Mexican patent in question expires.<br />

Curiously enough, the timeframes for both procedures do<br />

not always match. The timeframe for obtaining a marketing<br />

authorisation normally lasts between three to six months and<br />

up to one year, whereas a patent application will normally take<br />

longer, approximately four years, on average. Therefore, there is<br />

a mismatch between the time that the innovator can benefit from<br />

having an active ingredient monopoly and the time during which it<br />

can generate revenue from the monopoly.


MexicoData<br />

“<br />

These guidelines were drafted with the<br />

intention to be in line with the minimum time term set<br />

by NAFTA and advise that a marketing authorisation<br />

holder will have a five-year exclusive right<br />

So far, so good. However, since 2008, the Mexican regulation was<br />

amended to include a requirement for the approval of generic drugs<br />

before COFEPRIS on the sole basis of interchangeability tests.<br />

That is, generic companies may obtain marketing authorisation<br />

for a generic product by merely providing dissolution profiles or<br />

bioavailability studies.<br />

As the reader might infer, this intrinsically means that a generic<br />

product applicant indirectly benefits from the safety and efficacy<br />

studies already carried out by the innovator, which, in part, might<br />

explain why generic products are almost always cheaper than their<br />

innovator counterparts.<br />

These facts uncover a clear disconnect between IP rights, sanitary<br />

regulatory affairs, and clinical data protection, not in the sense that<br />

there is a breakage in the confidentiality of clinical data, but in the<br />

lack of observance to international related treaties to which Mexico<br />

is bound.<br />

Considering that the Mexican Constitution positions a hierarchy<br />

of international treaties approved by the Mexican Senate over<br />

Federal Laws, clinical data protection in Mexico should in theory<br />

be strictly subject to either of the following two legal international<br />

dispositions: the North American Free Trade Agreement (NAFTA)<br />

and Trade-Related Aspects of IP Rights (TRIPS) Agreement.<br />

Indeed, these are back by further local legislation, including the<br />

Mexican IP Law, Mexican Health Law, Mexican Health Products<br />

Regulations, and the Mexican General Health Law Regulations for<br />

Health Researching.<br />

On the one hand, while the Mexican IP Law establishes that<br />

undisclosed information in an application for marketing authorisation<br />

shall be regarded as a trade secret, it also states that information<br />

submitted in order to obtain an authorisation to produce or market<br />

chemical products shall be protected according to the international<br />

treaties to which Mexico is a signatory.<br />

On the other hand, as part of these two treaties, a minimum fiveyear<br />

term of indirect reliance on data protection/exclusivity would<br />

be expected to circumvent prejudicial commercial use of the<br />

confidential information made available by the innovator to the<br />

local sanitary regulatory authority, COFEPRIS.<br />

However, there are no provisions in any of the local Mexican<br />

regulations containing a ‘non-reliance’ period as established in<br />

international treaties such as NAFTA and TRIPS. This means that<br />

during a data exclusivity period, the innovator’s pre-clinical and<br />

clinical trials data should not be referenced in the regulatory filings<br />

57<br />

”<br />

of another company (typically a generic company) for the same<br />

drug substance.<br />

Soledad Betanzos-Lara, Lawyer, Goodrich, Riquelme y Asociados<br />

This period, according to Article 1711 of NAFTA, shall begin from<br />

the date on which the marketing authorisation is granted to the<br />

requesting party. NAFTA’s wording is subject to interpretation<br />

as regards to a reliance on the product safety and efficacy data<br />

contained in the dossier, because Section 6 of Article 1711 reads:<br />

“Each party shall provide that for data subject to Paragraph 5 that<br />

are submitted to the party after the date of entry into force of this<br />

agreement, no person other than the person that submitted them<br />

may, without the latter’s permission, rely on such data in support<br />

of an application for product approval during a reasonable period<br />

of time after their submission.<br />

For this purpose, a reasonable period shall normally mean no less<br />

than five years from the date on which the party granted approval<br />

to the person that produced the data for approval to market its<br />

product, taking account of the nature of the data and the person’s<br />

efforts and expenditures in producing them. Subject to this<br />

provision, there shall be no limitation on any party to implement<br />

abbreviated approval procedures for such products on the basis of<br />

bioequivalence and bioavailability studies.”<br />

In an attempt to provide for this missing link, in 2012, COFEPRIS<br />

published on its website a memorandum providing guidelines<br />

for observing the absent regulatory data package exclusivity<br />

agreement. These guidelines were drafted with the intention to be<br />

in line with the minimum time term set by NAFTA and advise that<br />

a marketing authorisation holder will have a five-year exclusive<br />

right, during which its clinical-related information cannot benefit<br />

or be used to support a third-party application for registration of<br />

a generic drug. Nevertheless, generic companies are invited to<br />

provide their own standard clinical trials to obtain the corresponding<br />

marketing authorisation if they so wish.<br />

Theoretically, this sounds very promising. Practically, not<br />

much has been achieved: not a single relevant case in Mexico<br />

entreating international data protection treaties has been filed<br />

as of today.<br />

Mexico has accomplished enormous advances in this respect,<br />

although there are still some evident loopholes in the Mexican<br />

legislation regarding IP rights and clinical data protection framed in<br />

the scope of sanitary regulatory affairs. Considering the imminent<br />

global tendency towards stronger and harmonised IP protection,<br />

Mexico will have to make its legislation fit. IPPro


a break between the law and commercial reality?<br />

Experts from Christodoulos G. Vassiliades & Co. LLC examine the ways in<br />

which Europe and the UK have recently approached shape trademarks


Cadbury’s opposition to the decision of the UK Intellectual Property<br />

Office (IPO) to accept the registration of Kit Kat’s shape as a<br />

trademark was seen, by many, as the cherry on top of a war without<br />

a herald, especially following the opposition by Nestlé of Cadbury’s<br />

application to register its Dairy Milk colour, purple, back in 2014.<br />

But following a series of decisions, beginning with the one from the<br />

UK IPO and leading up to a referral by Justice Richard Arnold to<br />

the Court of Justice of the EU (CJEU), it seems that this is more<br />

than a mere feud between chocolate giants. The courts seem be<br />

making a bold statement about registering shapes as trademarks,<br />

thereby clarifying that although the same criteria apply, the extent<br />

of their application differs. This is in line with a more general trend<br />

towards giving applicants of shape trademarks a “harder time”<br />

when applying for such registrations.<br />

Indeed, it can be argued that the decisions reached so far were<br />

taken (as far as distinctiveness is concerned) because of Nestlé’s<br />

inability to present palpable evidence that the Kit Kat’s shape<br />

(without the word mark) has been sufficiently branded, advertised<br />

and recognised among the relevant public.<br />

Nonetheless, it seems that the landmark principle that this case<br />

establishes is the extension of Article 3(1)(e)(ii), specifically the<br />

term ‘technical result’, beyond the function of the goods to the<br />

manner in which they are manufactured.<br />

On 8 July 2010, Nestlé submitted an application to the UK IPO<br />

for the registration of its four-finger shape as a trademark. The<br />

application, which was only considered on absolute grounds, was<br />

accepted ex-officio.<br />

Cadbury opposed the decision of the UK IPO by arguing the<br />

following, which may be divided into two main grounds:<br />

• Ground one: Article 3 (1) (b), (c) and (d) of the Directive<br />

2008/95/EC; and a lack of acquired distinctiveness as per<br />

Article 3(3).<br />

• Ground two: Article 3(1)(e)(i); and/or Article 3(1) (e) (ii).<br />

Both parties presented expert evidence in support of their<br />

arguments. Seemingly, the most contributive of these experts<br />

were: the senior project engineer for Cadbury, Mark Robertson,<br />

and Philip Malivoire for Nestlé, who was responsible for the two<br />

surveys conducted in 2007 and 2012, respectively, on behalf<br />

of Nestlé.<br />

Robertson said there are two main means of producing<br />

confectionary: enrobing and moulding. He rejected enrobing as<br />

a means of achieving Kit Kat’s shape on the basis that it “does<br />

not provide a sufficiently strong base or attachments between the<br />

individual fingers”.<br />

He then proceeded to explain that the release of chocolate moulded<br />

products required sloping sides with minimum angle of 8 to 10<br />

degrees (Kit Kat having a 14 degrees angle). He also explained<br />

that the grooves indicated to the consumer where to break the<br />

bars. It was, nonetheless, submitted on cross-examination that the<br />

initial concept of a new product is produced by the marketing team.<br />

Robertson was found by the IPO as a credible and honest witness,<br />

with the latter adding considerable substance to his submissions.<br />

59<br />

ShapeMarks<br />

The fact that almost the entire shape of Kit Kat was explained<br />

in simple technical terms was a blow on Kit Kat’s case, at least<br />

in relation to the second ground. As far as the first ground is<br />

concerned, the blow came from Nestlé itself.<br />

Malivoire conducted two surveys for Nestlé; one in 2007 and the<br />

other in 2012. The first survey was found as non-compliant with<br />

the criteria set out by the court in recognising such surveys. The<br />

most important factor for non-compliance was the high degree<br />

of speculation in which the person answering the question<br />

embarked upon.<br />

The second survey was accepted as evidence. It showed at least<br />

half of the respondents recognised Kit Kat’s shape.<br />

However, neither this nor the fact that Nestlé heavily invested in<br />

promoting the product, assisted Nestlé’s case, and justifiably so.<br />

“<br />

The ground<br />

of acquired distinctiveness<br />

suffered a big blow, which<br />

Nestlé could have avoided<br />

in commercial terms,<br />

if the commercialisation<br />

and the branding and<br />

marketing strategy<br />

for Kit Kat was more<br />

consistent throughout<br />

the years and more<br />

in line with their ultimate<br />

purpose, namely that of the<br />

registration of Kit Kat as a<br />

shape mark<br />

”<br />

Christodoulos Vassiliades, Managing partner, Christodoulos G. Vassiliades & Co. LLC


ShapeMarks<br />

Especially as far as Kit Kat’s branding is concerned (in relation to<br />

the four-finger shape), the same could not be proved in numbers.<br />

Nestlé was only able to provide that between the years of 1996 and<br />

2007, it spent between £3 and £11 million per annum promoting<br />

the Kit Kat product in the UK alone—most of which was directed<br />

toward the four-finger version.<br />

However, presented with the relevant evidence, the examiner could<br />

not identify the shape mark that was the subject of the application.<br />

Further, between 2008 and 2010, Nestlé spent between £850,000<br />

and £4.4 million in promoting the products, again without being<br />

able to determine the percentage of that expenditure dedicated<br />

in the promotion of the shape in question (2010 being the year in<br />

which Nestlé applied for registration of the shape trademark).<br />

Although it remained indisputable that the market share of Kit Kat<br />

was between 1 and 2 percent of the chocolate market during that<br />

period (a percentage, which, if taken in context, is considerably<br />

high), the ground of acquired distinctiveness suffered a big blow,<br />

which Nestlé could have avoided in commercial terms, if the<br />

commercialisation and the branding and marketing strategy for Kit<br />

Kat was more consistent throughout the years and more in line with<br />

their ultimate purpose, namely that of the registration of Kit Kat as<br />

a shape mark.<br />

Justice Arnold, although clearly in favour of the decision of the<br />

UK IPO, seemed eager to clarify three main questions, which he<br />

referred to the CJEU:<br />

• In order to establish that a trademark has acquired a distinctive<br />

character following the use that had been made of it within<br />

the meaning of Article 3(3) of the directive, is it sufficient<br />

for the applicant for registration to prove that at the relevant<br />

date, a significant proportion of the relevant class of persons<br />

recognise the mark and associate it with the applicant’s goods<br />

in the sense that, if they were to be asked who marketed the<br />

goods bearing that mark, they would identify the applicant; or<br />

must the applicant provide that a significant proportion of the<br />

relevant class of persons rely upon the mark (as opposed to<br />

any other trademarks that may also be present) as indicating<br />

the origin of the goods?<br />

• Where a shape consists of three essential features, one of<br />

which results from the nature of the goods themselves and<br />

two of which are necessary to obtain a technical result, is<br />

registration of that shape as a trademark precluded by Article<br />

3(1)(e)(i) and/or (ii) of the directive?<br />

• Should Article 3(1)(e)(ii) of the directive be interpreted as<br />

precluding registration of shapes that are necessary to obtain<br />

a technical result with regard to the manner in which the<br />

goods are manufactured as opposed to the manner in which<br />

the goods function?<br />

The UK IPO based its decision on the strict letter of the law,<br />

therefore deciding that Kit Kat’s shape could not be registered due<br />

to both grounds: the first, because acquired distinctiveness could<br />

not be proved; and the second, because the shape of Kit Kat was<br />

dictated by the natural shape of the goods and by the technical<br />

results it produced (although the registration for the shape mark in<br />

relation to cakes and pastries was accepted).<br />

60<br />

As with the previous decisions on this matter the advocate<br />

general’s opinion on the first question was clear: “The function of<br />

a trademark is an essential element of its distinctive character.”<br />

Therefore, it is not enough to associate a shape mark with another<br />

trademark of the same trade origin. The shape mark needs to be<br />

able to function as a trademark, ie, lead the consumer straight to


ShapeMarks<br />

the trade origin and not to another trademark (in this case, to the<br />

word mark Kit Kat).<br />

This, as the very essence of trademark law, seems to have been<br />

applied in a very firm manner. The advocate general’s application<br />

of this principle to combined trademarks and to trademarks existing<br />

in conjunction with other trademarks was stated as follows:<br />

trademarks that are used in combination or in conjunction with<br />

other trademarks—and have acquired distinctiveness as a result—<br />

may be individually registered, provided that they are capable<br />

of functioning as a trademark (individually), ie, are capable of<br />

distinguishing the goods of one undertaking from those of another<br />

and therefore used as a batch of origin (which was essentially a<br />

reinstatement of advocate general Juliane Kokott’s opinion in<br />

Nestlé (C-353/03)). After all, the decision does not deviate from the<br />

common standard practices, namely that despite the many functions<br />

of a trademark, the only function that is officially recognised is the<br />

denotation of origin. Nonetheless, in a commercial context applied<br />

specifically to the merits of this case, one could argue differently.<br />

The overall impression drawn by the decisions mentioned above<br />

is that the shape mark was or could easily be associated with<br />

Kit Kat, albeit not directly with Nestlé. However, for a chocolate<br />

giant such as Nestlé, which holds 1 to 2 percent of the chocolate<br />

market in the UK, the association of Kit Kat with Nestlé, and as<br />

a result, the shape mark with Nestlé, cannot be but a simple<br />

mathematical equation.<br />

In light of the above, one would wonder whether the strict<br />

application of the letter of the law was intentional or due to a<br />

number of contributing factors: the first being the lack of supporting<br />

evidence in relation to distinctiveness, and the second, the need to<br />

make sure that shapes are limited to design protection (which, after<br />

all, is only limited to 25 years of protection).<br />

If the first ground is taken in isolation, and considering the bold<br />

example of the Coca-Cola bottle, one could argue that commercial<br />

considerations do step in, or are at least considered along with<br />

legal as well as policy considerations in finding distinctiveness<br />

(provided that such commercial considerations are well supported,<br />

which was not the case here). But if this case is perceived in its real<br />

context, Article 3(1) (e)(i) and (ii) seem to have been the main factors<br />

used to determine the outcome.<br />

The advocate general here found that two grounds, namely shapes<br />

dictated by the nature of the goods and shapes that are necessary<br />

to obtain a technical result, cannot be applied cumulatively,<br />

although they can be applied separately to the same mark.<br />

As far as the nature of the goods is concerned, the advocate general<br />

clarified that Article 3(1)(e)(ii) is not and should not be limited to the Lego<br />

(C-48/09) and Philips v Remington cases (C-299/99).<br />

Rather, the interpretation approach adopted was purposive<br />

rather than literal meaning that the public interest behind this<br />

provision dictates that a technical result could result from both:<br />

the function of the goods as well as the manner in which these are<br />

manufactured. So long as any one of these is applied, the shape<br />

mark should not be registered.<br />

As a result of the application of both grounds:<br />

• The basic rectangular slab was held to fall within Article<br />

3(1(e)(i);<br />

• The presence of breaking grooves was held to fall within<br />

Article 3(1)(e)(ii);<br />

• An angle of more than 8 to 10 degrees fell within Article 3(1)<br />

(e)(i) and the depth of the same within Article 3(1)(e)(ii); and<br />

• The number of breaking grooves and fingers was held as<br />

been determined by the desired portion size.<br />

Therefore, in contrast to the acquired distinctiveness ground,<br />

the first ground serves as an important public interest function.<br />

It prohibits the protection of technical solutions or functional<br />

characteristics, which would and should normally be protected<br />

under patents or designs, and for whatever reason they<br />

cannot, from being protected as trademarks (exclusively and<br />

permanently). Further, it provides a ‘fair trade’ defence to<br />

competitors in the sense that it protects competitors from being<br />

deprived of technical solutions that the consumer may seek or<br />

demand to see in their products.<br />

Admittedly, the opinion of the advocate general was expected<br />

and, as with the rest of the decisions on this matter, is well<br />

supported. Now it remains to be seen whether or not the CJEU<br />

will follow the leads of the preceding judgements, although it is<br />

highly unlikely that the EU’s highest court or the national court<br />

will rule to the contrary. IPPro<br />

“<br />

It provides a ‘fair trade’ defence to<br />

competitors in the sense that it protects them from<br />

being deprived of technical solutions that the consumer<br />

may seek or demand to see in their products<br />

”<br />

Ourania Vrondou, Advocate and head of intellectual property department,<br />

Christodoulos G. Vassiliades & Co. LLC<br />

61


AfricaTrademarks<br />

OAPI: effective trademark protection<br />

Vanessa Halle of Nico Halle & Co Law Firm offers some useful tips<br />

for brands protecting and enforcing their trademark rights in Africa<br />

With the marked increase in trademark registrations at the African<br />

Intellectual Property Organization (commonly known by its French<br />

acronym OAPI), one can assume that most brand owners are<br />

aware of the importance of protecting their trademarks.<br />

OAPI is an organisation comprised of 17 member states: Benin,<br />

Burkina Faso, Cameroon, the Central African Republic, Chad,<br />

Comoros Islands, Congo Brazzaville, Cote d’Ivoire, Equatorial<br />

Guinea, Gabon, Guinea Bissau, Guinea Conakry, Mali, Mauritania,<br />

Niger, Senegal, and Togo.<br />

An application filed at OAPI is protected in all 17 member states.<br />

Once filed at OAPI, a brand owner has the exclusive right to exploit<br />

its trademark, as well as prevent third parties from making use of<br />

identical or similar trademarks for similar goods or services without<br />

authorisation. The maintenance and protection of a trademark can<br />

take multiple forms.<br />

Renewals and related procedures<br />

The main form of maintaining a trademark is by renewal. A<br />

trademark is valid for 10 years from the filing date, and is preserved<br />

indefinitely through successive renewals done every 10 years.<br />

When the trademark is not renewed within the 10-year deadline, it<br />

can be renewed within a six-month grace period.<br />

If this six-month period elapses and the trademark has still not been<br />

renewed as a result of circumstances beyond the control of the<br />

brand owner, there is a final opportunity to restore the trademark,<br />

62<br />

through a process known as ‘restoration’. This procedure must be<br />

brought within six months of the grace period elapsing, and no<br />

later than two years of the renewal date.<br />

As per Article 21(6) of Annex 3 of the Revised Bangui Agreement<br />

(RBA), where a mark has not been renewed, it can only be registered<br />

for the benefit of a third party in respect of identical or similar goods<br />

or services when three years from the renewal date have elapsed.<br />

However, note Article 25(4) of Annex 3 of the RBA, which further<br />

states that third parties that start to use the mark after it has not<br />

been renewed will have the right to continue doing so.<br />

With these two seemingly paradoxical articles, brand owners are<br />

encouraged to renew their trademarks within the deadline, rather<br />

than delay and renew during the grace period or via restoration.<br />

This is because allowing the trademark to lapse creates loopholes<br />

for infringers to exploit, as they have the option to simply use the<br />

trademark, rather than register.<br />

Opposition actions<br />

Upon registration of a trademark, it is published in the OAPI<br />

official bulletin. An opposition action must be brought within six<br />

months of this date. This option allows a brand owner to oppose<br />

the registration of a mark that is similar or identical to its own and<br />

relates to the same goods or services, where such a similarity is<br />

liable to mislead or confuse the public.


AfricaTrademarks<br />

Any brand owner wishing to effectively protect its trademark<br />

using this route should retain a reliable and professional watch<br />

service to monitor the registry and inform on any similar and or<br />

identical trademarks.<br />

This could be seen by some as an average means of protection<br />

at OAPI because it does not reject trademarks on grounds of<br />

similarity—an interested party must oppose the trademark.<br />

Furthermore, an applicant can commence commercialisation of a<br />

trademark immediately upon filing at OAPI.<br />

When the timeframe from filing, registration, and eventual<br />

publication is taken into account, a period of at least two years<br />

can be envisaged. Also, during an opposition proceeding, the<br />

applicant of the allegedly infringing trademark has the right to<br />

continue exploitation until a decision is issued by OAPI cancelling<br />

the disputed trademark.<br />

In order for an infringement seizure to be effective, brand owners<br />

are advised to seize at the port of entry, ie, before the articles are<br />

disseminated into the market.<br />

Once the infringing products are circulated further in the territory<br />

or sent to other member states, it becomes more complicated<br />

and costly to monitor and bring infringement actions in several<br />

member states.<br />

It is therefore important to deal with these matters in a timely and<br />

prompt manner, as well as retain a reliable and diligent lawyer in<br />

the relevant member state to guide and assist during the seizure<br />

proceedings. IPPro<br />

It could be validly argued that the allegedly infringing party will<br />

have had at least two years to exploit the disputed trademark, to<br />

the detriment of the brand owner.<br />

Cancellation action<br />

Cancellation actions can be brought before the civil court, when a<br />

registered mark has not been used on the territory of at least one<br />

OAPI member state for an uninterrupted period of five years.<br />

One important aspect of the OAPI system is that use of a brand in<br />

at least one OAPI member state satisfies the requirement of use.<br />

Brand owners are therefore not compelled to exploit their brands in<br />

all the 17 member states.<br />

The burden of proof regarding use of a mark rests with the owner<br />

of a mark, and use by another person shall be recognised as use,<br />

subject to endorsement by the owner. Note that for use by another<br />

party to be enforceable in OAPI, it has to be recorded in the special<br />

register of marks.<br />

Invalidity action<br />

Invalidity actions are brought before the civil courts at the request<br />

either of the Office of Public Prosecution, or any interested party.<br />

The grounds for bringing this action are the same as that required<br />

for an opposition action (before OAPI). The only difference seems<br />

to be the absence of the requirement to bring the action within six<br />

months of the publication date in the OAPI official bulletin. The<br />

presumption of lengthy trials before the civil courts of the member<br />

states sometimes deters brand owners from using this route.<br />

It is therefore advised that in order to avoid going through the<br />

courts, brand owners should use a professional monitoring service<br />

to reliably and promptly inform them when a similar or identical<br />

trademark is published, so that an action can be brought before<br />

OAPI (as an opposition action), which though lengthy is relatively<br />

faster than court.<br />

Infringement action<br />

Infringement proceedings are brought by the brand owner before<br />

the civil courts and judged as summary proceedings. Note that for<br />

infringement seizure, security is always required of foreigners.<br />

63<br />

“<br />

One important<br />

aspect of the OAPI system<br />

is that use of a brand in<br />

at least one OAPI<br />

member state satisfies the<br />

requirement of use.<br />

Brand owners are<br />

therefore not compelled<br />

to exploit their<br />

brands in all the 17<br />

member states<br />

”<br />

Vanessa Halle, Director, intellectual property, Nico Halle & Co Law Firm


NigeriaPerspective<br />

Closing borders to fakers and pirates<br />

Amaka Okafor of Stillwaters Law outlines the importance of an<br />

effective border control regime to fighting counterfeiting and piracy<br />

Counterfeiting and piracy are presently acknowledged as great global<br />

threats to creativity. Counterfeiting is the act of unlawfully imitating<br />

or reproducing items/works protected by the law of trademarks,<br />

patents, or copyright, while portraying them as originals. This is<br />

usually represented in goods illegally bearing registered/wellknown<br />

trademarks. Piracy, on the other hand, is the unauthorised<br />

reproduction and distribution of such protected items/works without<br />

necessarily representing them as original. This is more common in<br />

copyrighted works, for example, the reproduction and sale of books<br />

or CDs containing video recordings.<br />

64<br />

Nigeria, like many other states, has various laws and regulatory<br />

measures against counterfeiting. Nevertheless, this illegal trade<br />

has not only grown over the years but has metamorphosed into a<br />

formidable, sophisticated, and largely ignored sector. For instance in<br />

Nigeria, pirated items are presently being sold openly on the streets.<br />

The International Federation of Phonographic Industry (IFPI), upon<br />

research conducted in 10 individual music markets including the UK,<br />

Germany, and the US, reported that approximately 20 billion songs<br />

were illegally downloaded in 2005. On 19 and 21 March 2015, it


NigeriaPerspective<br />

Due to the transnational nature of counterfeiting, one of the most<br />

effective ways to control it is to employ an effective border control<br />

measure to prevent the importation and circulation of these counterfeits.<br />

Enforcement of IP at Nigeria’s international borders is undertaken by<br />

several regulatory bodies which include: the National Agency for Food<br />

and Drug Administration and Control (NAFDAC), Nigerian Customs<br />

Service (NCS), Standards Organization of Nigeria and the Nigerian<br />

Copyright Commission. These bodies are governed by various national<br />

and international laws/treaties and they include: the Customs and Excise<br />

Management (Disposal of Goods) Act (CEMA); the Trade Related<br />

Aspects of IP Agreement popularly referred as the TRIPS Agreement;<br />

and the Paris Convention for the Protection of Industrial Property.<br />

The TRIPS Agreement<br />

The TRIPS Agreement was established primarily to address the<br />

insufficiency of the international IP enforcement regime. A significant<br />

innovation of this agreement is the introduction of border measures.<br />

The agreement allowed genuine manufacturers or right holders,<br />

reasonably suspecting the importation or exportation of pirated/<br />

counterfeited versions of their works, to make applications to the<br />

appropriate authorities (administrative or judicial) for the seizure of<br />

such counterfeits at borders by customs officials.<br />

Nigerian Customs Service and other agencies<br />

Customs is principally the ‘gatekeeper’ of every nation. Being the<br />

agency in charge of all goods entering, transiting and leaving the country<br />

through the international borders, its role in combating smuggling, and<br />

more specifically, counterfeiting, can never be overemphasised.<br />

was recorded that US Customs and Border Protection (CBP) officers<br />

seized more than $430,000 of counterfeit perfumes at the Champlain<br />

Port of Entry and $65,200 dollars in fake $100 bills coming from<br />

Ecuador at John F. Kennedy International Airport. More recently, on<br />

17 July 2015, it was reported that CBP officers seized more than<br />

1,100 pieces of fake designer jewellry valued at approximately<br />

$562,729 (manufacturer’s suggested retail price) at the port of<br />

Louisville, Kentucky. The Business Action to Stop Counterfeiting and<br />

Piracy (BASCAP) has estimated the value of these illegal trades to<br />

be globally worth $1.7 trillion.<br />

It is therefore incontrovertible that counterfeiting is a global issue.<br />

However, what is worrisome is that Nigeria has become a dumping<br />

ground for counterfeit goods and a safe haven for perpetrators of<br />

this vice, a situation that can largely be attributed to the lack of<br />

sensitisation and weakness of the Nigerian intellectual property<br />

enforcement regime.<br />

65<br />

In discharging this function the Nigerian Customs Service (NCS) has<br />

an enforcement, investigation, inspection, and intelligence department,<br />

which, among others, organises all anti-smuggling measures at<br />

international borders. It should be noted that irrespective of the NCS’s<br />

corroboration with various agencies in this regard (as will be examined<br />

shortly), the service performs the lead role.<br />

The NCS sets out various guidelines to assist in implementing its mandate.<br />

In 2010, the Presidential Task Force for 100% Inspection was established<br />

to prevent the importation of contraband goods and ensure the complete<br />

inspection of all consignments selected for physical examination. It<br />

involves a strategy where inspections are intensified on consignments<br />

with more tendencies to default, than on every shipment.<br />

The NCS has additionally established an independent unit, the Customs<br />

Intelligence Unit (CIU), with trained officials who are responsible for<br />

obtaining and gathering information necessary to combat counterfeiting<br />

and piracy.<br />

A very significant development is the NCS’s partnership with other<br />

federal agencies such as the Standards Organization of Nigeria (SON),<br />

National Agency for Food and Drugs Administration and Control<br />

(NAFDAC), National Drug Law Enforcement Agency (NDLEA) and<br />

Nigeria Copyright Commission (NCC), in carrying out joint inspection<br />

of cargo at borders.<br />

For instance, it was reported in 2012 that with the combined efforts<br />

of the NCC and NCS, 13 containers stacked with pirated items were<br />

confiscated at different seaports in Nigeria. Similarly in January 2015,<br />

it was reported that more than 19 containers, containing counterfeit


NigeriaPerspective<br />

pharmaceutical and medical products, worth more than N 270 million<br />

($13.5 million) were impounded at the Apapa Ports in Lagos, Nigeria,<br />

by NAFDAC officials along with the NCS.<br />

Challenges in the border control regime<br />

The various strategies employed to prevent the importation of<br />

counterfeits seem insufficient in light of the prevailing circumstances.<br />

Some of the key challenges encountered in the enforcement of these<br />

measures are worthy of mention.<br />

instance, at the just concluded World IP Day seminar (April 2015)<br />

sponsored and widely publicised by the IP Committee of the Section<br />

of Business Law branch of the Nigerian Bar Association, where<br />

information and knowledge about IP protection is shared, only a few<br />

rights holders were present<br />

The fight against counterfeiting is largely multifaceted with border<br />

control being just one arm. Still, it is more effective to seize a<br />

consignment of counterfeit or pirated goods at borders or in transit<br />

than after circulation of the goods in the market. Providing a successful<br />

“<br />

An improved coordinated border management scheme<br />

is highly recommended between the relevant agencies to<br />

improve communication and facilitate more efficient risk<br />

management procedures<br />

”<br />

Amaka Okafor, Associate, Stillwaters Law<br />

Low integrity among the staff of most of the key agencies involved in<br />

this process is one of the greatest challenges faced in the enforcement<br />

of border measures. Integrity is not only limited to bribery and corruption<br />

but also includes the inefficacy of the services provided. This has<br />

resulted in the loss of public trust, non-compliance by stakeholders,<br />

unnecessary obstacles in the supposedly normal processes, loss of<br />

trade and investment, consequential revenue loss, and much more.<br />

The NCS also presently operates under the CEMA, which is<br />

largely outdated and fails to provide adequate legal frameworks<br />

for the discharge of its functions. There is no legal basis for the<br />

implementation of major international agreements to which Nigeria<br />

is a signatory. Unlike Nigeria, states such as Australia, Canada, New<br />

Zealand, South Korea, Switzerland, Turkey, South Africa, Indonesia<br />

and the US have included similar provisions in their substantive IP<br />

laws and/or have enacted special laws, too. The Canadian Combating<br />

Counterfeit Products Act and the South African Counterfeit Goods Act<br />

are a few examples in this regard.<br />

As a result, modern techniques and enforcement procedures such as<br />

the TRIPS Agreement provisions on border measures, which have<br />

gained tremendous success internationally, have not been effectively<br />

implemented in Nigeria.<br />

The collaboration of the NCS with other federal agencies is unarguably<br />

very beneficial for the purpose. However, this strategy has been heavily<br />

criticised for amounting to a needless duplication of process, resulting in<br />

unnecessary delays and a reduction in the efficiency of these agencies.<br />

The ignorance and/or unwillingness of rights holders to enforce their<br />

IP and explore available remedies are also part of the problem. For<br />

66<br />

border control system would go a long way to curbing counterfeiting<br />

and piracy as the large number of counterfeits currently being flooded<br />

into the country would be contained.<br />

To achieve this, the gaps in the present border control regime must<br />

be addressed. There is an eminent need for: an overhaul of the<br />

current NCS legislation; an improvement in the funding and training<br />

of the relevant agencies and their officers; provision of regulatory<br />

and supervisory measures to checkmate corruption and integrity<br />

issues; the creation of massive public awareness campaigns on the<br />

dangers of piracy and counterfeiting, the existence of IPRs as well<br />

as the remedies and enforcement measures available; adequate<br />

sensitisation of stakeholders such as the officers of the relevant<br />

agencies; and the adoption of the single window system, which<br />

requires customers to deal with a single agency at customs rather<br />

than different agencies, to curb unnecessary delays.<br />

In the alternative, an improved coordinated border management scheme<br />

is highly recommended between the relevant agencies to improve<br />

communication and facilitate more efficient risk management procedures.<br />

The importance of coordination of border control measures in this regard<br />

can never be overemphasised. Nevertheless, this strategy is more likely<br />

to succeed if it goes beyond federal agencies to include other relevant<br />

stakeholders such as manufacturers, right holders, exporters, importers,<br />

carriers, and so on.<br />

Such coordination, if achieved, will go a long way to addressing most<br />

of the hiccups encountered in the present regime and ultimately<br />

strengthening Nigeria’s stance in combating counterfeiting and the<br />

importation of pirated materials. IPPro


PROTECTING GREAT IDEAS<br />

AROUND THE WORLD<br />

The world is full of ideas. Our idea is to help you turn your intangible<br />

assets into sustainable business value. So that you can create a long<br />

lasting difference between you and your competitors.<br />

That´s what we have been doing since 1870. Today we are represented<br />

in more than 120 countries.<br />

www.zacco.com


TurkishTrademarks<br />

Game-changing decisions on trademarks continue<br />

The Turkish Constitution and trademark law are at odds, but the courts are<br />

making attempts to clear up the disputes, says Oktay Simsek of Destek Patent<br />

The Constitutional Court has recently cancelled two important<br />

provisions of Trademark Decree Law No 556, which was issued in<br />

1995 and governs trademarks in Turkey, because terms prescribed<br />

in two of its articles violate the property rights of the individuals.<br />

The recent decisions of the Constitutional Court (2015/49 and<br />

2015/46), which were issued in May 2015, in respect of freedom of<br />

conscience and religion, property rights and freedom of expression<br />

issues, are quite resounding and have a direct and substantive<br />

impact on the lives of individuals and society. Intellectual<br />

and industrial property rights have been also affected by the<br />

Constitutional Court’s approach.<br />

The first case is related to assignment matters. In Turkey, it was<br />

previously not possible for rights holders to assign one trademark<br />

while keeping other identical or confusingly similar trademarks.<br />

The Turkish Patent Institute would invite the assignor to assign<br />

its other identical or confusingly similar trademarks within two<br />

months to make it possible to record the assignment in the<br />

trademark registry.<br />

That is based on the principle of single ownership of a trademark<br />

in Turkish practice. Essentially, it was not possible to for two<br />

68<br />

identical or confusingly similar trademarks to be recorded in the<br />

registry under different owners. According to Article 16(5) of the<br />

Trademark Decree Law No 556: “While a registered trademark<br />

being transferred, if the same holder holds another identical<br />

or confusingly similar trademark registration for identical or<br />

confusingly similar goods and services such, as to mislead the<br />

public, those trademarks should be also transferred.”<br />

The first case was brought by the Ankara Third Court of Intellectual<br />

and Industrial Property Rights on the following observations:<br />

• Property rights and basic rights and freedoms cannot be<br />

the subject of decree laws in the Turkish Constitution, and<br />

this is a matter for trademark rights, which are a kind of<br />

property right.<br />

• The limits of Article 16(5) are not clear, objective or<br />

equally applicable.<br />

• The article has a function surpassing its aim (ratio logic) since<br />

it grants large power to Turkish Patent Institute on a relative<br />

matter, namely deciding on the similarities of the goods and<br />

services, which means an interference with the rights for the<br />

freedom of contract.<br />

• The article is in conflict with basic rights and freedoms and the<br />

free market economy, since the state authority is overruled on


TurkishTrademarks<br />

the decision to whom a trademark will be granted or assigned.<br />

• The subject matter is not prescribed in the contemporary<br />

trademark law and EU Trademark Directive, a reference<br />

source for the present decree law while it was being drafted,<br />

do not comprise a limitation of this kind.<br />

• The currently applied single ownership principle in the<br />

trademark law is not in compliance with the modern trademark<br />

system and it remains ‘archaic’ since the registrability or<br />

assignability of a trademark is conferred on the public authority<br />

rather than on the trademark owner.<br />

This cancellation has opened a path for right holders to assign their<br />

rights for one or some of their trademarks while keeping others<br />

under their ownership.<br />

In Turkish trademark practice, a letter of consent, co-existence<br />

agreement or any other authorisation, is not allowed for registering<br />

an identical or confusingly similar trademark due to the single<br />

ownership principle. This hinges on Article 7(1)(b) of the same<br />

decree law, ie, any identical or confusingly similar trademark is<br />

not allowed for any identical or confusingly similar goods by the<br />

Turkish Patent Institute at the first instance of examination.<br />

The cancellation of Article 16(5) has made it possible to overcome<br />

provisional refusals by way of the ‘assign and assign-back strategy’.<br />

In other words, the party affected by the provisional refusal can,<br />

for awhile, have the rights of the trademarks indicated as grounds<br />

for refusal based on the agreement and assign them back after<br />

registering its own trademark.<br />

In another case, the Constitutional Court has cancelled Paragraph<br />

1(i) of Article 7, which covers absolute grounds for refusal.<br />

Article 7(1)(i) states that a well-known mark within the meaning of<br />

Article 6 of the Paris Convention, unless authorised by its owner,<br />

are not allowed to be registered.<br />

Based on this, the Turkish Patent Institute would refuse applications<br />

for well-known marks from third parties.<br />

The case was brought to the agenda of the Constitution Court by the<br />

Ankara Third Court of Intellectual and Industrial Property Rights with a<br />

cancellation request with the following remarks:<br />

• Property rights and basic rights and freedoms cannot be the<br />

subject of decree laws in the Turkish Constitution and this is a<br />

matter for trademark rights, which are a kind of the property rights.<br />

• The article has a function surpassing its aim (ratio logic) since<br />

it grants large power to Turkish Patent Institute on a relative<br />

matter, namely deciding on the similarities of the goods and<br />

services, which means an interference with the rights for the<br />

freedom of contract.<br />

• Any examination under Article 7(1)(i) would be performed on<br />

the basis of the subjective view of the examiner in charge. A<br />

subjective approach cannot be accepted for absolute grounds<br />

and the matters are a subject of Article 8, where the relative<br />

grounds are considered after publication and in view of the<br />

observations and evidence provided by the parties.<br />

• Any ex-officio refusal under Article 7(1)(i) would damage the<br />

essence of the rights, exceed the limits, and restrict individual<br />

rights and freedoms in a democratic state.<br />

The Constitutional Court has discussed the matter, deciding that<br />

Article 7(1)(i) should be cancelled due to the fact that decree laws<br />

cannot restrict property rights according to the constitution.<br />

The Turkish Patent Institute has not applied Article 7(1)(i) in too<br />

many of its decisions until now. In any case, the Turkish Patent<br />

Institute will not refuse well-known trademarks on absolute<br />

grounds any longer.<br />

Well-known trademark holders should be more attentive about<br />

monitoring identical or confusingly similar trademarks to have a<br />

chance of filing oppositions within three months after publication.<br />

The cancellations of the provisions of the two articles in question<br />

have also started a debate on the destiny of Article 7(1)(b),<br />

which has been criticised for its subjective and obsolete nature<br />

in view of the requirements of the modern commercial life and<br />

freedom of contracts.<br />

Taking into account that the Constitutional Court has cancelled<br />

other articles of the decree law in the past, it appears that more<br />

articles will be under attack for cancellation in the near future.<br />

While the new draft trademark law has been pending in parliament<br />

since 2009, these recent rulings show how necessary it is to<br />

introduce it without further delay, so that uncertainties plaguing<br />

trademark matters can be clarified. IPPro<br />

“<br />

Well-known trademark holders<br />

should be more attentive about monitoring identical or<br />

confusingly similar trademarks to have a chance of<br />

filing oppositions within three months after publication<br />

”<br />

Oktay Simsek, Head of foreign affairs department, Destek Patent<br />

69


An interview with Hugo T Berkemeyer<br />

What is your firm’s background?<br />

Since its foundation in 1951, Berkemeyer Attorneys and<br />

Counselors from Paraguay has provided expert legal services to<br />

clients at an international and local level, gaining a global reputation for<br />

quality, expertise and professionalism. Our firm provides legal advice on<br />

virtually all areas of law.<br />

Our practice also comprises intellectual property: trademarks,<br />

patents, the life sciences, copyright protection, utility models,<br />

industrial models and designs, domain names, franchising,<br />

enforcement, unfair competition and civil law, IP litigation, and<br />

sanitary registrations.<br />

At Berkemeyer Attorneys and Counselors we pride ourselves<br />

on our ability to meet clients’ needs directly, providing<br />

professional and practical advice of the highest quality,<br />

employing teamwork and collaboration to render the services<br />

in a thorough yet timely manner.<br />

How long have you been using the Patricia® software?<br />

We implemented the Patricia® software in 2011.<br />

Which software did you use before and how does<br />

it compare?<br />

Patricia® replaced our in-house system which helps us in the daily<br />

work due to the functionalities that allow us to do way more than<br />

just docketing.<br />

One of the main messages about how Patricia® differs from typical<br />

‘docketing’ systems is how it is so much more than just docketing.<br />

Patricia® is a full practice management solution. Which other<br />

areas of your practice, in addition to docketing, does Patricia®<br />

help you with?<br />

As one of the largest and most prestigious law<br />

firms in South America, what number of active<br />

cases do you currently have in in your IP practice?<br />

Over 3,000 cases.<br />

What advice would you give to other large IP firms<br />

considering change?<br />

Regarding advice for other companies, Patricia® is recommended<br />

and useful for the daily internal work, especially related to the<br />

control of the processes.<br />

In what way is Patricia® fundamental to ensuring/<br />

assisting your ongoing business success and<br />

how is it capable of helping you to monitor and<br />

improve levels of service to clients?<br />

Patricia® helps us to perform better administration of the cases<br />

which leads to a better control of the processes, including the due<br />

dates of trademark and patent maintenance payments. It helps us<br />

to provide faster and efficient answers to our clients.<br />

Although a growing company, Patrix has been eager<br />

to ensure that we always remain approachable at<br />

all levels. How do you find interacting with the<br />

Patrix team, from support up to the owner level?<br />

The team always provide a fast response to any inquiries from<br />

our users, which is very important when they have any issues<br />

to resolve.<br />

If you could give us one sentence which<br />

encapsulates your understanding of Patrix and<br />

Patricia® and what it does for your business,<br />

what would it be?<br />

Patricia® replaced an in-house developed system which<br />

covered the basic needs regarding patents and trademarks. Its<br />

functionalities allowed us to improve and expand the offered<br />

services to our clients, and to improve the internal process as well.<br />

It enhanced the control of the processes step by step in attention<br />

to due dates, costs, invoicing, related documents, etc. and overall<br />

the ease of the system to follow.<br />

Good! Patricia® has become a very useful tool in the daily<br />

improvement of our work. It supports us in the control and<br />

optimisation of our available resources.<br />

Would you swap Patricia® for any other IP<br />

software?<br />

We would not swap Patrix/Patricia® for any other IP software.


Extended DMS<br />

When your needs for document management<br />

surpasses the functions featured in the standard<br />

Patricia® document tab, we are happy to offer you<br />

the Patricia® Extended DMS. Efficient document<br />

management made accessible.<br />

Focus<br />

Think of all the hours spent looking for the right documents.<br />

Now think about all the time you could save if search ing for information<br />

was swifter and handling your docu ments was more<br />

efficient. Discover the potential of Patricia® Extended DMS.<br />

Sophisticated search<br />

Patricia® Extended DMS features a full-text search function that<br />

allows you to search for content within each document – or<br />

across the entire case document tree. Scanned PDF images can<br />

be transformed into text, and added to the search index. This<br />

means you’re also able to find scanned PDF documents by searching<br />

for text they contain.<br />

powerful preview<br />

Bringing traditional case management into the digital world, the<br />

preview function lets you flick through documents and view their<br />

content – just like browsing through a physical case file. A quick<br />

and intuitive way of finding and reviewing case documents.<br />

Versioning<br />

Not only does this feature allow you to track previous versions of<br />

documents without needing to access backup systems, it also<br />

lets you see the difference between versions. Documents can include<br />

a history of which user edited the document and on what<br />

date.<br />

Work where you want to<br />

Offline Work Mode lets you work on case documents outside the<br />

office. You can synchronize a case document folder before leaving<br />

the office, and work on the documents while you’re away.<br />

Then, when your laptop next connects to the office network,<br />

the Patricia® Extended DMS automatically synchronizes any local<br />

changes as a new version of the document to the server.<br />

>> Find your document fast, see what it contains and compare it<br />

to other versions. Take complete control of your case documents<br />

with Patricia® Extended DMS.


Black Knight Media<br />

www.blackknightmedialtd.com<br />

Tired of keeping these turning on your own?<br />

So are we<br />

To find out more about IPPro Connects, contact: carlosnorthon@ipprotheinternet.com


FirmProfiles<br />

Company description<br />

101domain, Inc<br />

Tel: +1 760 444 8674<br />

corporate@101domain.co<br />

www.101domain.co<br />

101domain is the trusted provider of corporate domain and brand protection services for many of the<br />

world’s leading organisations.<br />

With a broad service suite of management and detection solutions, domain strategy creation and acquisition<br />

experience, 101domain has succeeded in fortifying, securing, and expanding brand owners’ online<br />

presence for over 10 years.<br />

For corporations, navigating and managing the challenges of brand abuse and misuse on the internet can<br />

be a full-time effort. Trust 101domain to provide world-class support and expert guidance in minimising<br />

both the time and investment required to protect your online assets.<br />

73


FirmProfiles<br />

Company description<br />

bNamed.net<br />

Tel: +44 203 393 4858<br />

info@bnamed.net<br />

www.bNamed.net<br />

At bNamed.net, we feel that protecting your brand online shouldn’t cost you an arm and a leg. We<br />

offer a fusion between a normal domain registrar and a high-profile online brand protection service.<br />

Contrary to most brand protection services, we have normal end-user registration fees, but offer high-end<br />

professional support. We prefer a personal approach, so brand protection clients most often have their<br />

own account manager with us, but due to our clear focus on domain names, all our staff members have<br />

a thorough understanding of all of the ins and outs of domain name registrations.<br />

Founded in 1999, we have 16 years of experience in domain name registrations and we know the domain<br />

name market inside out. We offer every possible extension, and those that are otherwise hard to obtain.<br />

Next to every-day domain name registrations, we also offer advice on online brand protection and<br />

assist with purchasing a domain name or with gaining control over a domain name that’s infringing<br />

your trademark. When needed, we partner with a outside intellectual property firms to manage dispute<br />

resolution cases or other legal actions, but we can successfully solve most cases without having to<br />

involve expensive lawyers, which keeps your costs low.<br />

We assist with centralising and optimising domain name portfolios. Due to our experience and many local<br />

contacts, we can bypass local presence requirements in almost all countries with such strict registration<br />

conditions, making otherwise impossible registrations possible. And we know all of ins and outs of<br />

the different transfer procedures. If a transfer is stuck because the losing registrar, for example, isn’t<br />

cooperating, most often there are other ways of getting the transfer done.<br />

Company description<br />

Christodoulos G. Vassiliades & Co. LLC<br />

Tel: +357 22 55 66 77<br />

cgv@vasslaw.net<br />

www.vasslaw.com<br />

Christodoulos G. Vassiliades & Co. LLC is one of the leading law firms in Cyprus with expertise in<br />

corporate law, commercial law, trusts, mergers and acquisitions, and intellectual property law. Beyond the<br />

legal services offered, our firm also provides a full range of corporate administration and trust services.<br />

We are committed to professionalism and excellence in everything we do. We fully appreciate the<br />

diversity of legal and commercial needs clients have and are able to offer high standards of personalised<br />

advice in order to meet all our clients’ needs.<br />

The firm’s zeal towards innovation led to the founding of its IP department in 2008. Acknowledging the<br />

pivotal importance of protecting IP rights, we have established a team of enthusiastic IP experts, ready<br />

to assist with any type of right.<br />

Our key specialisations include community trademark services such as registration, renewals and<br />

oppositions, as well as international trademark services, namely registrations via the Madrid system.<br />

We pride ourselves in our effectiveness, efficiency and organisation, while recognising the need of our<br />

clients to remain ahead of important deadlines and obligations that constantly arise when maintaining<br />

IP rights.<br />

Our firm’s success in IP is to a great extent attributed to its circle of associates who share our passion for<br />

excellence, accuracy and promptness. This allows us to rely on and refer to them any matter requiring<br />

local counselling and representation. As a result, our firm may assist in any IP matter, not only confined<br />

within Cyprus and Europe but internationally as well.<br />

74


FirmProfiles<br />

Company description<br />

D Young & Co<br />

Tel: +44 (0)20 7269 8550<br />

mail@dyoung.com<br />

www.dyoung.com<br />

D Young & Co’s life sciences team is one of the leading intellectual property practices in Europe. Clients<br />

choose D Young & Co for IP services confident in the knowledge, experience and dedication that has<br />

characterised our work throughout our firm’s history.<br />

A depth of experience in all technical disciplines<br />

Attorneys in the life sciences team are highly qualified in a wide range of academic and technological fields,<br />

including biotechnology, chemistry, immunology, molecular biology, antibody technology, diagnostics,<br />

personalised medicine, stem cell technology, vaccines, food chemistry, optics, medical technology and<br />

pharmaceuticals. Many of our attorneys have practical experience working in academic environments, in<br />

the UK and European Patent Offices, and as in-house counsel for major companies. Our attorneys are<br />

able to use this experience to deliver strategic advice to clients, when and where it is required. A firm that<br />

is at the leading edge for patent prosecution.<br />

We are especially proud of our extensive experience before the EPO opposition division and technical<br />

boards of appeal. We regularly handle important and valuable contentious matters both for patentee<br />

and opponent, particularly in the fields of biotechnology, pharmaceuticals and petrochemicals. Clients<br />

value our commercial approach in guiding them through increasingly technical and complex regulation to<br />

ensure their IP rights are protected.<br />

A client base that is diverse and international<br />

D Young & Co has an enviable track record of working with academic and research institutions and<br />

spin outs, all of which have been at the forefront of innovation and life-changing discoveries. As well as<br />

servicing clients from all over the UK, we directly advise pharmaceutical, chemical and biotechnology<br />

companies across continental Europe, the US and Japan.<br />

A record that speaks for itself<br />

We are proud of the fact that D Young & Co is one of the very few IP firms to be ranked ‘top tier’ by all the<br />

independent major UK legal directories. These rankings are based on independent client feedback and<br />

this is what really counts.<br />

Company description<br />

Dennemeyer & Associates<br />

Tel: +352 27 6115 100<br />

info@dennemeyer-law.com<br />

www.dennemeyer.com<br />

Dennemeyer & Associates is the premier resource for global intellectual property law services—worldwide.<br />

For more than 50 years, Dennemeyer & Associates has been providing the full range of legal services<br />

relating to the core of your intellectual property management: your intellectual assets. Our lawyers offer<br />

world-class expertise in the following areas of IP law: patents, trademarks, designs, copyrights, domain<br />

names, IP contracts, licensing and recordals.<br />

Working in unison with Dennemeyer Group, a leading IP service provider, we offer a worldwide single point of<br />

contact for the full range of IP services, from legal services to comprehensive outsourcing solutions like portfolio<br />

services, cutting-edge software solutions, IP consulting, temporary staffing or full outsourcing of entire departments.<br />

Our main services include:<br />

Prosecution: searching, drafting applications (patents, utility models, designs, trademarks), monitoring third<br />

party applications, patent mapping, freedom-to-operate studies, filings, replies to office actions, translations,<br />

oppositions and appeals, European patent validations, grant and registration procedures, recordals, oral<br />

proceedings, intellectual property docketing, foreign filing and a web-based platform for PCT nationalisation,<br />

European patent validations and translations.<br />

Litigation: nullity actions, cancellation proceedings, court actions, counterfeits and cross-border action.<br />

Licensing law: licence contracts, coexistence agreements, copyrights.<br />

We have offices in seven countries: Luxembourg, Germany, the US, Japan, Poland, Romania and<br />

Australia. We have established a worldwide network of highly experienced professionals enabling us to<br />

cover almost all jurisdictions of the world in terms of prosecution and contentious work. We offer complete<br />

cost transparency and efficiency because we file and prosecute directly with many national patent and<br />

trademark offices.<br />

Our experts are qualified to work for you in the following technical and scientific fields, among many others:<br />

biochemistry, chemistry, pharmaceuticals, electrical engineering, electronics, mechanical engineering, IT and<br />

telecommunications. Whatever your industry, we are able to provide support in all technical areas and we<br />

continue to expand our service offerings, adapting to customers’ needs and providing cost-efficient solutions.<br />

75


FirmProfiles<br />

Company description<br />

Destek Patent<br />

Tel: +90 224 270 6600<br />

global@destekpatent.com.tr<br />

www.destekpatent.com<br />

Destek Patent has been a major force in intellectual property management and protection in Turkey, and<br />

has been providing a full range of IP services, including patents, trademarks, domain names, industrial<br />

designs and licensing, for both Turkish and overseas clients since 1983.<br />

The firm is a member of LES, AIPPI, INTA, MARQUES, PTMG, GRUR, EPI, VPP and TOBB.<br />

We understand clients’ needs and expectations on expert counselling, fast response, clear<br />

communication and cost effective quality IP services, an independent indicator of which is our high<br />

clients’ satisfaction rate.<br />

Company description<br />

Dreyfus & associés<br />

Tel: +33 1 4470 0704<br />

contact@dreyfus.fr<br />

www.dreyfus.fr<br />

Founded in 2004 by Nathalie Dreyfus, Dreyfus quickly became one of the top intellectual property law<br />

firms in France. The Dreyfus team is well equipped to assist companies with particular expertise in IP/<br />

IT matters in France, the EU and worldwide.<br />

In an increasingly complex economic and legal environment, it has become imperative to efficiently<br />

protect, enhance and defend the essential assets of a company. The Dreyfus purpose is to support its<br />

clients with all the flexibility and reactivity that its structure allows, while offering the most up-to-date<br />

skill-sets, especially regarding international issues in the field of new technologies.<br />

When confronting problems, Dreyfus assists its clients in decision-making processes concerning the<br />

management and valorisation of their IP titles in the business realm and on the internet.<br />

With a worldwide network, Dreyfus will represent companies in arbitration centres and courts all over<br />

the world in disputes concerning trademarks, designs, patents, copyright, domain names, new gTLDs,<br />

social networks, Google AdWords and IT.<br />

Advising major traditional industrial actors as well as small and medium-sized firms impacted by the<br />

rise of e-commerce and the increasing use of trademarks on the web, Dreyfus has mastered all the<br />

issues related to the online presence of companies.<br />

In addition, Dreyfus has established the Dreyfus IPweb internet platform, an intuitive and interactive<br />

tool. This platform aims to consolidate and summarise all the information available to Dreyfus clients.<br />

The firm’s expertise, investment and creativity ensure optimal management of trademarks and domain<br />

name portfolios. Dreyfus is probably the most advanced French firm in the area of the management<br />

and protection of IP rights.<br />

76


FirmProfiles<br />

Company description<br />

Goodrich, Riquelme y Asociados<br />

Tel: +52 55 5533 0040<br />

mailcentral@goodrichriquelme.com<br />

www.goodrichriquelme.com<br />

With more than 75 years of experience, Goodrich, Riquelme y Asociados has a long tradition of standing<br />

alongside its clients when helping them make their business objectives a reality. By means of a cross<br />

practice among service areas and industry teams, our carefully trained lawyers achieve an innovative<br />

approach towards the rendering of contemporary legal services tailored to the demanding business<br />

community worldwide.<br />

We pride ourselves in knowing what drives key industry sectors and are able to provide on a daily basis,<br />

the best creative and cost-effective business solutions beforehand. Our clients are medium-size, as well<br />

as leading global companies of numerous nationalities and economic sectors.<br />

Company description<br />

Gorodissky & Partners<br />

Tel: +7 495 937 6116 / 6109<br />

pat@gorodissky.ru<br />

www.gorodissky.com<br />

Gorodissky & Partners, the leading Russian intellectual property law firm, provides a full range of<br />

intellectual property services, including prosecution and enforcement of IP rights. It has the largest IP<br />

practice in Russia and among top 10 in Europe.<br />

The firm’s main office is in Moscow, and it has branch offices in St. Petersburg, N. Novgorod, Krasnodar,<br />

Samara, Ekaterinburg, Perm, Kazan (all in Russia), Technopark Sarov and Kiev (Ukraine).<br />

The firm provides clients and associates with professional and cost-effective services in wide variety<br />

of practice areas: patenting, inventions and utility models, trademarks, service marks and appellations<br />

of origin, industrial designs, plant varieties, copyright, technology transfer and licensing, IP valuation,<br />

litigation, domain names, and due-diligence, as well as patent searches, notarial services, translation of<br />

patent and scientific-technical documents.<br />

Gorodissky & Partners’s lawyers and patent/trademark professionals have significant experience<br />

in litigating IP matters before the civil courts and in arbitration proceedings. They have successfully<br />

represented foreign and domestic clients in a number of landmark cases related to the infringement of<br />

patent and trademark owners’ rights in Russia and abroad.<br />

Many of the firm’s lawyers and patent/trademark attorneys are post-graduates with advanced technical<br />

and legal degrees. They regularly attend IP courses and work with foreign law firms worldwide, they<br />

are frequent speakers at international IP conferences, and also authors of many publications in IP<br />

professional magazines.<br />

Gorodissky & Partners has an extensive national and worldwide experience in IP issues, including those<br />

arising in the post-Soviet territory (the Commonwealth of Independent States countries and Baltic states).<br />

The firm is responsible for around half of the foreign patent applications and one third of the trademark<br />

applications filed in Russia every year. The clients of Gorodissky & Partners range from major domestic,<br />

foreign and international companies to small and medium-sized businesses.<br />

77


FirmProfiles<br />

Company description<br />

IPzen<br />

Tel: +33 1 84 17 45 32<br />

contact@ipzen.com<br />

www.ipzen.com<br />

IPzen is a new intellectual property and management software. Designed by trademark attorneys for<br />

trademark attorneys, it is a modern web-based tool. It is cloud-hosted and available as a software-as-aservice<br />

solution. It will allow you to securely access your data from anywhere only by using a browser. IPzen<br />

includes all the features required by trademark attorneys—and even more. It is a modular system available<br />

in both enterprise and law firm editions, as well as a service in a shared environment.<br />

IPzen is an internet platform that aims at consolidating and summarising all information that IP law firms<br />

or organisations use to process. As a modular system, IPzen is also comprised of a docketing system,<br />

trademark management software, domain name management software, a diary to track deadlines and a<br />

monitoring module consolidating the entire trademark monitoring results.<br />

The Law Firm Edition includes specific features to control information published to clients and therefore<br />

guarantees confidentiality. Information may be published for client allowing users to access their data<br />

online and to save time on reporting. IPzen enables records traceability and instructions received by<br />

email and/or directly via the platform. Rights management is particularly fine-tuned, especially in limiting<br />

users’ access to certain folders or trademarks.<br />

IPzen services<br />

Harbor Technologies offers outsourcing services for the monitoring and management of intellectual property<br />

rights. These services are possible through the IPzen Ssoftware, which enables our clients to easily access<br />

their data and focus on legal matters rather than on the administrative tasks of portfolio management.<br />

Company description<br />

Julian Varbanov & Partners<br />

J. Varbanov & partners<br />

Tel: +359 2 986 5125<br />

jvp@jvpatents.com<br />

www.jvpatents.com<br />

J. Varbanov & partners is one of the oldest and leading intellectual property firms in Bulgaria. We provide<br />

professional and cost-effective services and quality advices on all aspects of industrial property matters<br />

for the territory of Bulgaria as well as for the EU.<br />

Our team is dealing with establishment, protection and enforcement of industrial property rights derived<br />

from patents, trademarks, and industrial designs, including validation of European patents in Bulgaria.<br />

Our staff is made up of Bulgarian and European patent, trademark and design attorneys with great<br />

experience. We do filings and representations before the Bulgarian Patent Office, OHIM, WIPO and EPI<br />

We represent clients before custom authorities in connection with the application of boarder measures<br />

and all kinds of anti-counterfeiting activities. We are members of INTA, ECTA, EPI, UNION of European<br />

Practitioners in Industrial Property, AIPPI and PTMG.<br />

78


FirmProfiles<br />

Company description<br />

Nico Halle & Co. Law Firm<br />

Tel: +237 33 42 64 79<br />

hallelaw@hallelaw.com<br />

www.hallelaw.com<br />

Founded by its senior managing partner, Nico Halle in 1986, Nico Halle & Co. Law Firm is bilingual<br />

(English and French), and one of the oldest intellectual property firms licensed by the African Intellectual<br />

Property Organization (OAPI) to provide IP services in Africa. In order to provide integrated, cross-border<br />

services to meet our clients’ domestic, regional and global needs, our firm works in partnership with other<br />

renowned law firms in several countries across the globe.<br />

Noted for our diligent, expeditious, ethical, and professional services, and with a prolific and committed<br />

team of over a dozen IP attorneys and professionals, we provide comprehensive premium IP protection<br />

services in patents, trademarks, industrial designs, utility models, domain names, unfair competition, and<br />

plant varieties, as well as coordinating multi-jurisdictional disputes in parallel proceedings.<br />

Our main services for Patents, trademarks, utility models and industrial designs include:<br />

Acquisition and maintenance: searches, registration applications, translations, grant and registration<br />

procedures, recordations, and renewals and annuity.<br />

Litigation: drafting and oral submissions for restorations, oppositions and claim to ownership actions,<br />

nullity actions, cancellation proceedings, appeals, counterfeits, and cross-border actions.<br />

We represent a diverse clientele that is made up of the biggest and leading brands in industries including,<br />

but not limited, to biotechnology, pharmaceuticals, mechanical and electrical engineering, apparel<br />

and allied corporations, fashion accessories, liquor, food and beverages, consumer goods, banks<br />

and accounting, computer software, telecommunication, electronics, cosmetics, telecommunications,<br />

telemarketing, entertainment, and media.<br />

Company description<br />

Park IP Translations, a Welocalize company<br />

Tel: +1 212 581 8870 7722<br />

info@parkip.com<br />

www.parkip.com<br />

Park IP Translations, a Welocalize company, provides translation, litigation and filing solutions for patent<br />

and legal professionals. We protect our clients’ most valued assets and global brands in nearly every<br />

jurisdiction in the world. We provide complete translation services in more than 157 languages and filingready<br />

documentation for more than 60 countries. We are a leader in patent prosecution and validation,<br />

litigation language services, patent translations and filing.<br />

We also provide general legal services for all types of corporate and legal documents. Park IP has 13<br />

global locations in the US, Europe and Asia. Park IP delivers the highest quality translation as a result of<br />

our ISO 9001:2008 certification.<br />

Park IP Translations, a Welocalize company, is a world leader in expert legal translation and foreign filing<br />

language services. Welocalize, founded in 1997, offers innovative translation and localisation solutions.<br />

Translating nearly one billion words a year, Welocalize and Park IP Translations provide specialised<br />

services to thousands of multinational corporations and global law firms.<br />

According to Common Sense Advisory, Welocalize is the fourth largest language service provider in the<br />

US and ninth largest in the world.<br />

79


FirmProfiles<br />

Company description<br />

Patrix<br />

Tel: +46 31 50 7760 / +1 703 879 4860<br />

mail@patrix.com<br />

www.patrix.com<br />

Patricia is widely regarded as the most user friendly, powerful and versatile intellectual property management<br />

software available today.<br />

From the CEO through to the support staff, the Patrix team has extensive previous IP experience having<br />

each worked in the corporate and/or practice areas of IP. You can therefore be sure that they fully understand<br />

your requirements at every level.<br />

Patricia is an enterprise-wide solution that provides you with swift and secure access to your case data<br />

and automatic tracking of IP lifecycles, including laws/regulations, standard forms, time and cost registration,<br />

invoicing, customisable reports, document creation, document management, and powerful batch<br />

processing functionality. Patricia is designed to easily accommodate and harmonise your best practice<br />

and procedures including collaboration both inside and outside of your organisation.<br />

Created by IP professionals for IP professionals, Patricia is a fully customisable IP management system<br />

uniquely delivered on Windows and web platforms or a combination of both.<br />

Company description<br />

Pointer Brand Protection<br />

Tel: +31 20 30 319 35<br />

enquiries@pointerbp.nl<br />

www.pointerbp.com<br />

Pointer Brand Protection offers a full online brand protecting solution. Our monitoring and enforcement<br />

anti-piracy software covers social media, online marketplaces, domains, web shops and download<br />

platforms. With our advanced and customised filters, we detect, prioritise and act against counterfeits<br />

and other brand abuses.<br />

Innovation within our company is one of our key successes. We protect brand owners better by<br />

implementing the newest technologies, methods and legislations. We do this not only with our software<br />

development, internal processes and projects, but also by knowing what new platforms and tools<br />

counterfeiters are using.<br />

Our strategy is to collect all online sales and content and prioritise the biggest infringers. Our dedicated<br />

brand protection analysts take immediate action against infringements from our customised brand<br />

protection dashboard. With an investigative perspective, we protect brands better online.<br />

80


FirmProfiles<br />

Company description<br />

RWS Group and innovia<br />

www.rws.com<br />

www.inovia.com<br />

RWS and inovia are the world’s leading experts in intellectual property translations and foreign patent<br />

filing. For more than 70 years combined, we have led the industry and helped more than 10,000 clients<br />

protect their IP and enforce their IP rights around the world.<br />

• Ensure top quality;<br />

• Cut costs and save resources; and<br />

• Simplify and streamline.<br />

Company description<br />

Stillwaters Law Firm<br />

Tel: +234 1 454 7179<br />

info@stillwaterslaw.com<br />

www.stillwaterslaw.com<br />

Stillwaters is a leading law firm in Nigeria that specialises in intellectual property, technology transfer,<br />

distributorship or franchising, licensing, boarder enforcement measures, customs-related assistance,<br />

regulatory compliance, litigation, company and commercial law, and tax. The firm operates from the<br />

commercial cities of Lagos and Abuja in Nigeria, with associate offices in Accra in Ghana and Duala in<br />

Cameroon.<br />

Professionalism, flexibility and innovation are the hallmarks of our practice. We value professional<br />

excellence, outstanding results and realise they both require creativity and hard work. We strive to gain<br />

every legal advantage for our clients while upholding the principles behind the practice of law. Over the<br />

years, we have acquired considerable experience and an enviable reputation for rendering quality legal<br />

services in our areas of specialisation.<br />

Practice representative clients include more than 660 foreign multinationals, publicly quoted companies,<br />

financial institutions, industries, small- and medium-size businesses and private entrepreneurs. Our<br />

practice is adequately equipped and well positioned to meet the challenges of legal practice in an everchanging<br />

technological age.<br />

81


FirmProfiles<br />

Company description<br />

WebTMS Ltd<br />

Tel: + 44 118 958 2002<br />

sales@ippo.com<br />

www.webtms.com<br />

WebTMS Limited and Intellectual Property Online have been providing and developing trademark<br />

management systems since 1997 and have regularly appeared at the top of independent user surveys<br />

of trademark management software. Additionally, we have over 500 unique clients globally, based on all<br />

continents using our flagship product: WebTMS.<br />

WebTMS is a comprehensive trademark management suite that builds on record keeping and<br />

docketing to support efficient trademark management with modules for every type of IP. As well as our<br />

award winning WebTMS software, the team are also renowned for their excellent customer support,<br />

expertly managed migration/conversion projects, and industry knowledge. We also listen to our clients’<br />

feedback about our software to continually develop and progress the software to constantly meet<br />

clients’ expectations and needs.<br />

WebTMS offers software subscriptions, hosted systems, and installed systems, so you can choose the<br />

best solution for managing your trademarks and related IP data. Our software is used by brand owners<br />

(including many companies from the top 100 most valuable brands), law firms (including a number of the<br />

largest international law firms), and trademark attorneys (from all around the globe). However, we have a<br />

solution for everyone regardless of your portfolio size. Some clients have under 100 records, others have<br />

in excess of 300,000 records. We also cater for everything in-between.<br />

WebTMS is ISO 9001:2008 certified and a member of ITMA, INTA, MARQUES, NDA, and PTMG.<br />

Get in touch today for your free demo account and/or presentation.<br />

Black Knight Media<br />

www.blackknightmedialtd.com<br />

Tired of using one of these?<br />

So are we<br />

To find out more about IPPro Connects, contact: carlosnorthon@ipprotheinternet.com<br />

HP IPPro connect ADvert.indd 1 29/09/2015 16:05<br />

82


Trademark Renewals: Find your flavor<br />

When it comes to renewing your trademarks, you are in control. Find out whether the<br />

cost-efficient Standard Renewals or the no-compromise Premier Renewals suits your<br />

organization better.<br />

Standard Renewals<br />

Our most affordable service yet.<br />

• Obtain unrivaled savings for portfolios of at least 200 records<br />

• Keep track of your receipts and instructions via our 24/7 Portal<br />

• Optional services (assignments, mergers, reclassifications,<br />

e-billing etc.) available on request<br />

Premier Renewals<br />

Maximum flexibility. No compromises.<br />

• Vast array of customizations to make sure it readily fits your<br />

requirements<br />

• Over five decades of experience and highly qualified staff<br />

• Dedicated client contact and personalized service<br />

Learn more:<br />

http://www.dennemeyer.com/contact/

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!